<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00602667</url>
  </required_header>
  <id_info>
    <org_study_id>SJYC07</org_study_id>
    <secondary_id>R01CA154619</secondary_id>
    <secondary_id>NCI-2011-01193</secondary_id>
    <nct_id>NCT00602667</nct_id>
  </id_info>
  <brief_title>Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma</brief_title>
  <official_title>Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Pew Charitable Trusts</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: In this study a combination of anti-cancer drugs (chemotherapy) is used to treat
      brain tumors in young children. Using chemotherapy gives the brain more time to develop
      before radiation is given. The chemotherapy in this study includes the drug methotrexate.
      This drug was an important part of the two clinical trials which resulted in the best
      survival results for children less than 3 years of age with medulloblastoma. Most patients
      treated on this trial will also receive radiation which is carefully targeted to the area of
      the tumor. This type of radiation (focal conformal or proton beam radiotherapy) may result in
      fewer problems with thinking and learning than radiation to the whole brain and spinal cord.

      PURPOSE: This clinical trial is studying how well giving combination chemotherapy together
      with radiation therapy works in treating young patients with newly diagnosed central nervous
      system tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients with medulloblastoma who were diagnosed prior to their 3rd birthday will
      contribute to both the biology and therapeutic primary objectives of this protocol.
      Furthermore patients who were ≥3 and &lt;5 years old at the time of diagnosis will also be
      included in the cohort for these primary objectives as long as they meet the eligibility
      criteria as outlined in Amendment 8.0 of this protocol. Patients in the 3-5 year old age
      cohort who enrolled on previous versions of this protocol and who do not meet the criteria as
      outlined in Amendment 8.0 of this protocol will be excluded from the outcome analyses of the
      biology and therapeutic primary objectives of the protocol.

      OBJECTIVES:

      Primary

        -  To identify patterns of methylation profiling that are associated with progression-free
           survival among young pediatric patients with medulloblastoma treated with risk-adapted
           therapy.

        -  To estimate the event-free survival distribution of young medulloblastoma patients
           treated with risk-adapted therapy.

      Secondary

        -  To perform high-resolution genome-wide analyses of chromosomal abnormalities and gene
           expression patterns, and evaluate the relationship of these to other clinicopathological
           variables.

        -  To evaluate specific tumor types for molecular abnormalities with suspected prognostic
           or therapeutic significance.

        -  To evaluate the feasibility of collecting frozen and fixed tumor samples for analysis
           using high-resolution molecular biology tools.

        -  To estimate the event-free and overall survival of patients treated with the proposed
           risk-adapted therapy regimen, and to descriptively compare these survival rates to
           historical controls.

        -  To estimate the rates of local and distant disease progression in patients treated with
           focal radiotherapy (RT) to the post-operative tumor bed using a 5 mm clinical target
           volume margin.

        -  To estimate the objective response rate (sustained for 8 weeks) to induction
           chemotherapy including high-dose intravenous methotrexate for patients with residual or
           metastatic disease.

        -  To evaluate the feasibility and toxicity of administering low-dose intravenous
           vinblastine in conjunction with induction chemotherapy to patients with metastatic
           disease.

        -  To evaluate the feasibility and toxicity of administering consolidation therapy
           including cyclophosphamide and pharmacokinetically targeted topotecan to patients with
           metastatic disease, and to estimate the sustained (for 8 weeks) objective response rate
           (complete response and partial response) to such therapy in patients with measurable
           residual disease after induction.

        -  To evaluate the feasibility and toxicity of administering oral maintenance therapy in
           young children.

        -  To use quantitative magnetic resonance (MR) measures (volumetric, diffusion, and
           perfusion) of young brain tumor patients receiving chemotherapy including high-dose
           intravenous methotrexate to assess impact of treatment on developing brain.

        -  To investigate the feasibility of using PET as an in-vivo dosimetric and distal edge
           verification system for patients treated with proton beam therapy (for participants
           enrolled at St Jude only).

      OUTLINE: This is a multicenter study. Patients are stratified according to disease risk
      (low-risk vs intermediate-risk vs high-risk). Therapy consists of risk adapted induction,
      consolidation and maintenance chemotherapy. Focal irradiation is given to intermediate risk
      patients who have reached at least 12 months of age upon completion of induction.
      Intermediate risk patients who have not will receive low risk chemotherapy to delay RT until
      the age of 12 months.

      Patients may consent to provide tumor tissue and blood samples for biological studies. Tumor
      tissues are analyzed for the activation of the wnt signaling pathway (β-catenin), activation
      of the shh signaling pathway (Gli-1/SFRP1), and ERBB2; validation of novel patterns of gene
      expression via immunohistochemical (IHC) analysis; loss of chromosomes 6, 8p, 9q22,
      isochromosome 17q; amplification of MYCC, MYCN, and MYCL; validation of genetic abnormalities
      via interphase fluorescence in situ hybridization (iFISH); construction of gene expression
      profiles via microarray analysis; single nucleotide polymorphism (SNP) analysis for DNA
      purity and integrity using UV spectrophotometry and agarose gel electrophoresis;
      amplification of DNA via PCR and a combination of previously published and 'in-house'
      generated primers; potential oncogenes and tumor suppressor genes via DNA sequence analysis;
      expression of a number of cell signal proteins implicated in the biology of medulloblastoma
      via western blot; expression of additional proteins encoded by genes associated through SNP
      and gene expression array analysis with clinical disease behavior; and differential
      expression pattern of genes detected using microarray analysis via RT-PCR. DNA extraction and
      construction of tissue microarrays (TMAs) from tumor tissue will also be used for future IHC
      and FISH analysis. Blood samples are analyzed for constitutional DNA from patients whose
      tumors contain gene mutations via sequence analysis of constitutional DNA; cyclophosphamide
      and its metabolites via liquid chromatography mass spectroscopy method; topotecan lactone via
      isocratic high-performance liquid chromatography assay with fluorescence detection; and
      alpha-1-acid glycoprotein (AAGP) concentrations via immunoturbidimetric assay.

      After completion of study treatment, patients are followed every 6 months for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 17, 2007</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Actual">September 27, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Probability of Progression-free Survival (PFS) for Medulloblastoma Patients</measure>
    <time_frame>From date on treatment until date of first progression or relapse or disease related death or date of last contact, estimated at 1 year after treatment</time_frame>
    <description>Progression was defined as 25% increase in the size of any measurable lesion; the appearance of a new lesion; or the conversion of negative cerebrospinal fluid (CSF) cytology to positive. Defined as the time interval from date on treatment until the date of first progression, medulloblastoma-related death or date of last contact for patients who have not experienced an event. All eligible medulloblastoma patients who received any methotrexate are included in this analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Probability of Progression-free Survival (PFS) for Medulloblastoma Patients by DNA Methylation Subgroup</measure>
    <time_frame>From date on treatment to date of first progression or relapse or disease related death or date of last contact, estimated at 1 year after treatment</time_frame>
    <description>Defined as the time interval from date on treatment until the date of first progression, medulloblastoma-related death or date of last contact for patients who have not experienced an event. Eligible medulloblastoma patients who received any methotrexate and had molecularly confirmed medulloblastoma are included in this analysis. Five patients were excluded as 3 had no archival tissue available and 2 were found to not be medulloblastoma by methylation profile.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Probability of Event-free Survival (EFS) for Medulloblastoma Patients</measure>
    <time_frame>From date on treatment to date of first progression, relapse, second malignancy or death from any cause or to date of last contact, estimated at 1 year after</time_frame>
    <description>Defined as the time interval from date on treatment until the date of first progression, second malignancy or death due to any cause; or date of last contact for patients who have not experienced an event. All eligible medulloblastoma patients who received any methotrexate are included in this analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Chromosomal Abnormalities</measure>
    <time_frame>Based on samples obtained at the time of initial surgery or repeat surgery prior to treatment</time_frame>
    <description>Amplifications and deletions (gains and losses) for chromosomes of interest are shown in the table of measured values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of Patients With Gene Alterations</measure>
    <time_frame>Based on samples obtained at the time of initial surgery or repeat surgery prior to treatment</time_frame>
    <description>Gene alterations, which include single nucleotide variants (SNPs), amplifications, deletions, translocations, indels, and germline alterations are shown for specific genes of interest in the results table.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of Patients With Molecular Abnormalities by Tumor Type</measure>
    <time_frame>Based on samples obtained at the time of initial surgery or repeat surgery prior to treatment</time_frame>
    <description>Alterations included single nucleotide variants (SNPs), amplifications, deletions, translocations, indels, and germline alterations. Cytogenetic information shows gains and losses as specified in the table of measured values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Successful Collections for Frozen and Fixed Tumor Samples</measure>
    <time_frame>Based on samples obtained at the time of initial surgery or repeat surgery prior to treatment</time_frame>
    <description>Successful collections will be defined as the number of patients who have frozen/fixed tumor samples available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free Survival (EFS) Compared to Historical Controls</measure>
    <time_frame>From date on treatment until date of first event (progression, second malignancy or death) or until date of last contact, assessed up to 10 years</time_frame>
    <description>EFS was measured from the date of initial treatment to the earliest date of disease progression, second malignancy or death for patients who fail; and to the date of last contact for patients who remain at risk for failure. 1-year EFS estimates are reported by risk group. EFS was compared to St. Jude historical cohorts by risk group using hazard ratios with 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Compared to Historical Controls</measure>
    <time_frame>1 year after treatment initiation of last patient</time_frame>
    <description>OS was measured from the date of initial treatment to date of death or to date of last contact for survivors. 1-year OS estimates were reported by risk group. OS was compared to St. Jude historical cohorts by risk group using hazard ratios with 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Objective Responses Rate to Induction Chemotherapy</measure>
    <time_frame>From on-study date to 2 months after completion of induction chemotherapy (up to 4 months after on-study date)</time_frame>
    <description>For patients treated in the intermediate and high risk strata with residual or metastatic disease we will estimate the stratum-specific objective response rate (complete response (CR) or partial response [ PR]). All patients who receive at least 1 -dose of methotrexate are evaluable for response. Objective responses must be sustained for at least eight weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility and Toxicity of Administering Vinblastine With Induction Chemotherapy for Patients With Metastatic Disease as Measured by the Percentage of Courses Delayed for More Than 7 Days Due to Toxicity</measure>
    <time_frame>From on-study date up to 4 months after on-study date</time_frame>
    <description>For the subset of patients with metastatic disease (high-risk group patients), during induction, the proportion percentage of courses during which subsequent chemotherapy administration was delayed for more than 7 days due to toxicity will be calculated. Patients were to receive 4 courses of induction and then consolidation chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility and Toxicity of Administering Consolidation Therapy Including Cyclophosphamide and Pharmacokinetically Targeted Topotecan to Patients With Metastatic Disease Based on the Percentage of Courses Delayed for More Than 7 Days Due to Toxicity</measure>
    <time_frame>At completion of consolidation therapy (up to 6 months after on-study date)</time_frame>
    <description>For the subset of patients with metastatic disease (high-risk group patients), during consolidation, we will calculate the number and proportion of courses during which subsequent chemotherapy administration was delayed for more than 7 days due to toxicity. Patients were to received 2 courses of consolidation chemotherapy and then maintenance therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients With Sustained Objective Responses Rate After Consolidation</measure>
    <time_frame>8 weeks after completion of consolidation therapy (up to 8 months after on-study date)</time_frame>
    <description>For patients enrolled on the high-risk arm with measurable residual disease after induction treated with consolidation therapy, we will estimate the objective response (complete response (CR)/partial response (PR)) rate after consolidation therapy with a 95% confidence interval. Objective responses must be sustained for at least eight weeks. All patients who receive at least 1 dose of cyclophosphamide or topotecan during consolidation are evaluable for response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility and Toxicity of Administering Oral Maintenance Therapy in Children &lt;3 Years of Age as Measured by the Percentage of Total Scheduled Maintenance Doses Received</measure>
    <time_frame>From start of oral maintenance therapy (approximately 6 months after on-study date) to completion of oral maintenance therapy (up to 1 year after on-study date)</time_frame>
    <description>These data are based on patient diaries. For children &lt;3 years of age, we will calculate the percentage of total scheduled doses each patient received per course for each of the oral maintenance courses and report the overall average number percentage of doses received per course across patients. If patients received all planned doses, their percentage would be 100%. If the average percentage was less than 75%, then feasibility would be in question.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neurostructure, Especially White Matter Volume and Integrity</measure>
    <time_frame>From baseline to 60 months off therapy</time_frame>
    <description>Quantitative MRI measures of change in neurostructure (especially white matter volume and integrity) over time will be assessed using a random effects model incorporating various covariates. Covariates to be considered include age at diagnosis, time since diagnosis and risk-arm. Differences in quantitative MRI measures of neurostructure volume and integrity between patient groups will be evaluated as a metric of structural neurotoxicity of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of PET Scans With Loss of Signal Intensity</measure>
    <time_frame>Up to 3 times during RT consolidation</time_frame>
    <description>Measures will be analyzed for intermediate risk participants who receive proton beam therapy (PBT) and who consent. This objective aims to assess the feasibility of using post-proton beam therapy (PBT) positron emission tomography (PET) as an in-vivo dosimetric and distal edge verification system in this patient population. To quantify the decay in signal, 134 scans from 53 patients were analyzed by recording the mean activation value (MAV), the average recorded PET signal from activation, within the target volume. With each patient being given the same dose, the percent standard deviation in the MAV can serve as a quantitative representation of signal loss due to radioactive decay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Concentration of Cerebrospinal Fluid (CSF) Neurotransmitters</measure>
    <time_frame>Baseline, at the completion of therapy, and every 12 months up to 36 months after off therapy date</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neurocognitive Performance</measure>
    <time_frame>Baseline, at the completion of therapy, and every 12 months up to 60 months off therapy</time_frame>
    <description>Age standardized performance on measures of global cognitive functioning, attention, processing speed and executive functions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Type of Genetic Polymorphisms</measure>
    <time_frame>At study enrollment (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenetic Variation on CNS Transmitters</measure>
    <time_frame>At study enrollment (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neuropsychological Performance</measure>
    <time_frame>Baseline, 6- and 12-months from treatment initiation, and yearly after the first year (up to 5 years)</time_frame>
    <description>The primary interest is in global cognitive functioning. This is measured using the SB-V Routing subtests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quantitative Magnetic Resonance (MR) Measures in the Frontal Lobe</measure>
    <time_frame>Baseline and up to 60 months after completion of therapy.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neurocognitive Performance in Attention, Working Memory, and Fluency</measure>
    <time_frame>Baseline and prior to cycle A1 (~6 months) and at end of therapy and at 12, 24, 36, 48 and 60 months after completion of therapy.</time_frame>
    <description>Neurocognitive performance is assessed using a comprehensive battery of standard tests. Sustained attention is measured using the TOVA; selective auditory attention is measured using the WJIII; nonverbal attention span is measured using the SB-V Block Span subset. Working memory is measured using the WJIII. Fluency is measured using is also measured using the WJIII.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quantitative MR Measures in the Right Frontal-parietal Regions</measure>
    <time_frame>Baseline and up to 5 years after completion of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neurocognitive Performance in Visual-spatial Reasoning and Processing Speed</measure>
    <time_frame>Baseline and up to 5 years after completion of therapy.</time_frame>
    <description>Processing speed will be measured using the WJIII. Visual perception and visual-motor integration will be measured using the Beery VMI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Endocrinopathy</measure>
    <time_frame>Baseline, end of therapy, and at 6- and 24-months after completion of therapy</time_frame>
    <description>Serial GH testing (at baseline, the end of therapy, and at 6 and 24 months after completion of therapy) will be performed on consenting patients in order to estimate longitudinal change in GH secretion as measured by mean peak GH values, with the intent to explore associations with radiation dose to the hypothalamus. Since determination of proton- or photon-based radiotherapy is not based on randomization, it will not be possible to compare the endocrine outcome between the patients with and without PBT. However, the differences between these two clinical cohorts with respect to clinical and demographic variables of interest will be summarized via descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal Change in Growth Hormone Secretion</measure>
    <time_frame>Baseline, end of therapy, and at 6- and 24-months after completion of therapy</time_frame>
    <description>The intent of this objective is to estimate the longitudinal change in abnormal GH secretion as measured by mean peak GH values via a mixed effects model for the patients who receive PBT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methotrexate Clearance in Induction Cycle 1</measure>
    <time_frame>Pre-infusion and 6, 23, 42, 66 hours from start of Methotrexate (MTX)</time_frame>
    <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 1. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate clearance are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methotrexate Clearance in Induction Cycle 2</measure>
    <time_frame>Pre-infusion and 6, 23, 42, 66 hours from start of MTX</time_frame>
    <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 2. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate clearance are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methotrexate Clearance in Induction Cycle 3</measure>
    <time_frame>Pre-infusion and 6, 23, 42, 66 hours from start of MTX</time_frame>
    <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 3. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate clearance are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methotrexate Clearance in Induction Cycle 4</measure>
    <time_frame>Pre-infusion and 6, 23, 42, 66 hours from start of MTX</time_frame>
    <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 4. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate clearance are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methotrexate Volume of Central Compartment in Induction Cycle 1</measure>
    <time_frame>Pre-infusion and 6, 23, 42, 66 hours from start of MTX</time_frame>
    <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 1. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate volume of central compartment are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methotrexate Volume of Central Compartment in Induction Cycle 2</measure>
    <time_frame>Pre-infusion and 6, 23, 42, 66 hours from start of MTX</time_frame>
    <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 2. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate volume of central compartment are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methotrexate Volume of Central Compartment in Induction Cycle 3</measure>
    <time_frame>Pre-infusion and 6, 23, 42, 66 hours from start of MTX</time_frame>
    <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 3. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate volume of central compartment are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methotrexate Volume of Central Compartment in Induction Cycle 4</measure>
    <time_frame>Pre-infusion and 6, 23, 42, 66 hours from start of MTX</time_frame>
    <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 4. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate volume of central compartment are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methotrexate AUC0-66h in Induction Cycle 1</measure>
    <time_frame>Pre-infusion and 6, 23, 42, 66 hours from start of MTX</time_frame>
    <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 1. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate AUC0-66h (area under concentration curve from time 0 to 66 hours post-dose) are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methotrexate AUC0-66h in Induction Cycle 2</measure>
    <time_frame>Pre-infusion and 6, 23, 42, 66 hours from start of MTX</time_frame>
    <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 2. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate AUC0-66h (area under concentration curve from time 0 to 66 hours post-dose) are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methotrexate AUC0-66h in Induction Cycle 3</measure>
    <time_frame>Pre-infusion and 6, 23, 42, 66 hours from start of MTX</time_frame>
    <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 3. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate AUC0-66h (area under concentration curve from time 0 to 66 hours post-dose) are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methotrexate AUC0-66h in Induction Cycle 4</measure>
    <time_frame>Pre-infusion and 6, 23, 42, 66 hours from start of MTX</time_frame>
    <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 4. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate AUC0-66h (area under concentration curve from time 0 to 66 hours post-dose) are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methotrexate Concentration at 42 Hours Post-dose in Induction Cycle 1</measure>
    <time_frame>42 hours from start of MTX</time_frame>
    <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 1. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate concentration at 42 hours post-dose are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methotrexate Concentration at 42 Hours Post-dose in Induction Cycle 2</measure>
    <time_frame>42 hours from start of MTX</time_frame>
    <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 2. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate concentration at 42 hours post-dose are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methotrexate Concentration at 42 Hours Post-dose in Induction Cycle 3</measure>
    <time_frame>42 hours from start of MTX</time_frame>
    <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 3. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate concentration at 42 hours post-dose are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methotrexate Concentration at 42 Hours Post-dose in Induction Cycle 4</measure>
    <time_frame>42 hours from start of MTX</time_frame>
    <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 4. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate concentration at 42 hours post-dose are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cyclophosphamide Clearance in Induction Chemotherapy</measure>
    <time_frame>Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion</time_frame>
    <description>Cyclophosphamide plasma concentration-time data are collected on day 9 in one cycle of induction chemotherapy. Individual estimates of cyclophosphamide clearance are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cyclophosphamide Clearance in Consolidation Chemotherapy Cycle 1</measure>
    <time_frame>Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion</time_frame>
    <description>Cyclophosphamide plasma concentration-time data are collected in consolidation cycle 1. Individual estimates of cyclophosphamide clearance are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cyclophosphamide Clearance in Consolidation Chemotherapy Cycle 2</measure>
    <time_frame>Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion</time_frame>
    <description>Cyclophosphamide plasma concentration-time data are collected in consolidation cycle 2. Individual estimates of cyclophosphamide clearance are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cyclophosphamide Apparent Oral Clearance in Maintenance Chemotherapy Cycle A1</measure>
    <time_frame>Pre-dose, 0.5, 1.75, 3 and 6 hours post-dose</time_frame>
    <description>Cyclophosphamide plasma concentration-time data are collected on day 1 of maintenance cycle A1. Individual estimates of cyclophosphamide apparent oral clearance are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cyclophosphamide AUC0-24h in Induction Chemotherapy</measure>
    <time_frame>Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion</time_frame>
    <description>Cyclophosphamide plasma concentration-time data are collected on day 9 in one cycle of induction chemotherapy. Individual estimates of cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cyclophosphamide AUC0-24h in Consolidation Chemotherapy Cycle 1</measure>
    <time_frame>Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion</time_frame>
    <description>Cyclophosphamide plasma concentration-time data are collected in consolidation cycle 1. Individual estimates of cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cyclophosphamide AUC0-24h in Consolidation Chemotherapy Cycle 2</measure>
    <time_frame>Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion</time_frame>
    <description>Cyclophosphamide plasma concentration-time data are collected in consolidation cycle 2. Individual estimates of cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cyclophosphamide AUC0-24h in Maintenance Chemotherapy Cycle A1</measure>
    <time_frame>Pre-dose, 0.5, 1.75, 3, 6, and 24 hours post-dose</time_frame>
    <description>Cyclophosphamide plasma concentration-time data are collected on day 1 of maintenance cycle A1. Individual estimates of cyclophosphamide AUC0-24h are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-OH Cyclophosphamide AUC0-24h in Induction Chemotherapy</measure>
    <time_frame>Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion</time_frame>
    <description>4-OH cyclophosphamide plasma concentration-time data are collected on day 9 in one cycle of induction chemotherapy. Individual estimates of 4-OH cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-OH Cyclophosphamide AUC0-24h in Consolidation Chemotherapy Cycle 1</measure>
    <time_frame>Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion</time_frame>
    <description>4-OH cyclophosphamide plasma concentration-time data are collected in consolidation cycle 1. Individual estimates of 4-OH cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post- dose) are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-OH Cyclophosphamide AUC0-24h in Consolidation Chemotherapy Cycle 2</measure>
    <time_frame>Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion</time_frame>
    <description>4-OH cyclophosphamide plasma concentration-time data are collected in consolidation cycle 2. Individual estimates of 4-OH cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post- dose) are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-OH Cyclophosphamide AUC0-24h in Maintenance Chemotherapy Cycle A1</measure>
    <time_frame>Pre-dose, 0.5, 1.75, 3, 6, and 24 hours post-dose</time_frame>
    <description>4-OH cyclophosphamide plasma concentration-time data are collected on day 1 of maintenance cycle A1. Individual estimates of 4-OH cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CEPM AUC0-24h in Induction Chemotherapy</measure>
    <time_frame>Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion</time_frame>
    <description>Carboxyethylphosphoramide mustard (CEPM) plasma concentration-time data are collected on day 9 in one induction cycle. Individual estimates of CEPM AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CEPM AUC0-24h in Consolidation Chemotherapy Cycle 1</measure>
    <time_frame>Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion</time_frame>
    <description>Carboxyethylphosphoramide mustard (CEPM) plasma concentration-time data are collected in consolidation cycle 1. Individual estimates of CEPM AUC0-24h (area under concentration curve from time 0 to 24 hours post- dose) are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CEPM AUC0-24h in Consolidation Chemotherapy Cycle 2</measure>
    <time_frame>Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion</time_frame>
    <description>Carboxyethylphosphoramide mustard (CEPM) plasma concentration-time data are collected in consolidation cycle 2. Individual estimates of CEPM AUC0-24h (area under concentration curve from time 0 to 24 hours post- dose) are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CEPM AUC0-24h in Maintenance Chemotherapy Cycle A1</measure>
    <time_frame>Pre-dose, 0.5, 1.75, 3, 6, and 24 hours post-dose</time_frame>
    <description>Carboxyethylphosphoramide mustard (CEPM) plasma concentration-time data are collected on day 1 of maintenance cycle A1. Individual estimates of CEPM AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Empirical Dosage Achieving Target System Exposure of Intravenous Topotecan</measure>
    <time_frame>Pre-infusion, 5 min., 1, and 3 hours from end of infusion</time_frame>
    <description>Number of participants who successfully achieve target systemic exposure of intravenous topotecan after an empiric dosage during consolidation phase of therapy are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With PK-guided Dosage Adjustment Achieving Target System Exposure of Intravenous Topotecan</measure>
    <time_frame>Pre-infusion, 5 min., 1, and 3 hours from end of infusion</time_frame>
    <description>Number of participants who successfully achieve target systemic exposure of intravenous topotecan after a pharmacokinetic-guided dosage adjustment during consolidation phase of therapy are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Topotecan Clearance in Consolidation Chemotherapy</measure>
    <time_frame>Pre-infusion, 5 min., 1, and 3 hours from end of infusion</time_frame>
    <description>Topotecan plasma concentration-time data are collected on day 1 of consolidation cycle 1 after a single IV dose. Individual estimates of topotecan clearance are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Topotecan Apparent Oral Clearance in Maintenance Chemotherapy</measure>
    <time_frame>Pre-dose, 0.25, 1.5 and 6 hours post-dose</time_frame>
    <description>Topotecan plasma concentration-time data are collected on day 1 of maintenance cycle A1 after a single oral dose. Individual estimates of topotecan apparent oral clearance are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Topotecan AUC0-24h in Consolidation Chemotherapy</measure>
    <time_frame>Pre-infusion, 5 min., 1, 3, and 24 hours from end of infusion</time_frame>
    <description>Topotecan plasma concentration-time data are collected on day 1 of consolidation cycle 1 after a single IV dose. Individual estimates of topotecan AUC0-24h (area under concentration curve from time 0 to 24 hours post- dose) are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Topotecan AUC0-24h in Maintenance Chemotherapy</measure>
    <time_frame>Pre-dose, 0.25, 1.5, 6, and 24 hours post-dose</time_frame>
    <description>Topotecan plasma concentration-time data are collected on day 1 of maintenance cycle A1 after a single oral dose. Individual estimates of topotecan AUC0-24h (area under concentration curve from time 0 to 24 hours post- dose) are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erlotinib Apparent Oral Clearance</measure>
    <time_frame>Pre-dose, 1, 2, 4, 8, and 24 hours post-dose</time_frame>
    <description>Erlotinib plasma concentration-time data are collected on day 1 of maintenance cycle B2. Individual estimates of erlotinib apparent oral clearance are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erlotinib Apparent Volume of Central Compartment</measure>
    <time_frame>Pre-dose, 1, 2, 4, 8, and 24 hours post-dose</time_frame>
    <description>Erlotinib plasma concentration-time data are collected on day 1 of maintenance cycle B2. Individual estimates of erlotinib apparent volume of central compartment are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erlotinib AUC0-24h</measure>
    <time_frame>Pre-dose, 1, 2, 4, 8, and 24 hours post-dose</time_frame>
    <description>Erlotinib plasma concentration-time data are collected on day 1 of maintenance cycle B2. Individual estimates of erlotinib AUC0-24h (area under concentration curve from 0 to 24 hours post-dose) are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OSI-420 AUC0-24h</measure>
    <time_frame>Pre-dose, 1, 2, 4, 8, and 24 hours post-dose</time_frame>
    <description>Erlotinib metabolite OSI-420 plasma concentration-time data are collected on day 1 of maintenance cycle B2. Individual estimates of OSI-420 AUC0-24h (area under concentration curve from 0 to 24 hours post-dose) are obtained using post hoc analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Local Disease Progression</measure>
    <time_frame>1 year after completion of radiation therapy for last patient</time_frame>
    <description>Local failure was defined as the interval from end of RT to date of local failure (or combined local + distant failure). Competing events were distant failure or second malignancy. Patients without an event were censored at date of last contact. The 1-year cumulative incidence was estimated and reported with a 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Distant Disease Progression</measure>
    <time_frame>1 year after completion of radiation therapy for last patient</time_frame>
    <description>Distant failure was defined as the interval from end of RT to date of distant failure (or combined local + distant failure). Competing events were local failure or second malignancy. Patients without an event were censored at date of last contact. The 1-year cumulative incidence was estimated and reported with a 95% confidence interval.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">293</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>Low-Risk Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with GTR/M0 medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.
Note: Accrual to the low-risk medulloblastoma cohort is closed as of 12/2/2015. Accrual to the low-risk high grade glioma remains open.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Risk Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with CNS metastatic disease will receive induction chemotherapy and high-risk therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate-Risk Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Induction Chemotherapy</intervention_name>
    <description>All patients will receive 4 identical cycles of induction chemotherapy including highdose (5 g/m2 or 2.5g/m2 for patients less than or equal to 31 days of age at enrollment) intravenous methotrexate and standard dose vincristine, cisplatin, and cyclophosphamide.</description>
    <arm_group_label>High-Risk Patients</arm_group_label>
    <arm_group_label>Intermediate-Risk Therapy</arm_group_label>
    <arm_group_label>Low-Risk Patients</arm_group_label>
    <other_name>MTX (methotrexate)</other_name>
    <other_name>Oncovin(R) (vincristine)</other_name>
    <other_name>Platinol-AQ(R) (cisplatin)</other_name>
    <other_name>Cytoxan(R) (cyclophosphamide)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low-Risk Therapy</intervention_name>
    <description>Induction will be followed by further conventional chemotherapy with carboplatin, cyclophosphamide, and etoposide. After consolidation, patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).</description>
    <arm_group_label>Low-Risk Patients</arm_group_label>
    <other_name>Cytoxan(R) (cyclophosphamide)</other_name>
    <other_name>Paraplatin(R) (carboplatin)</other_name>
    <other_name>Vepesid(R), VP-16 (etoposide)</other_name>
    <other_name>Hycamptin(R) (topotecan)</other_name>
    <other_name>Tarceva(TM) (erlotinib)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High-Risk Therapy</intervention_name>
    <description>High risk patients will also receive vinblastine with each course of induction chemotherapy. Induction will be followed by either chemotherapy with targeted intravenous topotecan and cyclophosphamide or optional craniospinal irradiation (CSI). CSI will be offered only to patients who reach 3 years of age by the end of induction only. After consolidation, all patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).</description>
    <arm_group_label>High-Risk Patients</arm_group_label>
    <other_name>Velban(R) (vinblastine)</other_name>
    <other_name>Cytoxan(R) (cyclophosphamide)</other_name>
    <other_name>Hycamptin(R) (topotecan)</other_name>
    <other_name>Tarceva(TM) (erlotinib)</other_name>
    <other_name>Vepesid(R), VP-16 (etoposide)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intermediate-Risk Therapy</intervention_name>
    <description>Induction will be followed by consolidation focal radiotherapy (RT) to the tumor bed. Patients less than 12 months old upon completion of induction will receive low risk chemotherapy to delay RT until the age of 12 months. After consolidation, patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).
Note: The option to receive focal proton beam irradiation was suspended 10/29/2015. Focal photon beam irradiation continues as part of the treatment plan.</description>
    <arm_group_label>Intermediate-Risk Therapy</arm_group_label>
    <other_name>Cytoxan(R) (cyclophosphamide)</other_name>
    <other_name>Hycamptin(R) (topotecan)</other_name>
    <other_name>Tarceva(TM) (erlotinib)</other_name>
    <other_name>Vepesid(R), VP-16 (etoposide)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Histologically confirmed newly diagnosed CNS tumors of any of the following :

          -  Medulloblastoma (all histologic subtypes, including medullomyoblastoma and melanotic
             medulloblastoma)

          -  Supratentorial primitive neuroectodermal tumor (PNET) (including CNS neuroblastoma or
             ganglioneuroblastoma, medulloepithelioma, and ependymoblastoma)

          -  Pineoblastoma

          -  Atypical teratoid rhabdoid tumor (ATRT)

          -  Choroid plexus carcinoma

          -  High grade glioma (including anaplastic astrocytoma, anaplastic oligodendroglioma,
             anaplastic ganglioglioma, pleomorphic xanthoastrocytoma with anaplastic features,
             high-grade astroblastoma , anaplastic pilocytic astrocytoma, malignant glioneuronal
             tumor, glioblastoma multiforme), or gliosarcoma,

          -  Ependymoma (including all ependymoma histological variants)

          -  Age &lt; 3 years at time of diagnosis for all histological diagnosis. Medulloblastoma
             patients ≥ 3 and &lt; 5years old at diagnosis who have non-metastatic disease with no
             more than 1cm2 of residual tumor are also eligible.

               -  Meets criteria for 1 of the following risk groups:

          -  Low-risk group:

               -  Histologically confirmed nodular desmoplastic medulloblastoma, including
                  medulloblastoma with extensive nodularity

                    -  Focal areas of anaplasia or other atypical features suggesting more
                       aggressive phenotype in a tumor otherwise considered nodular desmoplastic
                       should be treated on the intermediate-risk group, with final risk
                       stratification at the discretion of principal investigator and study
                       pathologist

               -  No evidence of CNS metastasis 7 to 28 days after surgery by MRI and cytologic
                  examination of lumbar cerebrospinal fluid (CSF)

                    -  Ventricular CSF from a shunt or Ommaya reservoir may be used to rule out M1
                       disease when lumbar puncture is medically contraindicated

                    -  Intermediate-risk group assignment when there is no other evidence of
                       metastasis and CSF sampling is not possible

               -  Gross total resection, defined as residual tumor or imaging abnormality (not
                  definitive for residual tumor) with a size of &lt; 1 cm2 confirmed on postoperative
                  CT scan or MRI

               -  Brain stem invasion by the tumor in the absence of imaging evidence of residual
                  tumor (tumor size &lt; 1 cm2) and otherwise meets criteria for the low-risk group,
                  the patient will be classified as low-risk

               -  Desmoplastic medulloblastoma patients who are ≥3 -&lt;5 years of age will NOT be
                  eligible for the low risk arm of the protocol.

          -  Intermediate-risk group:

               -  Histologically confirmed nodular desmoplastic medulloblastoma with less than
                  gross total resection and no evidence of metastasis

               -  Any eligible histologic diagnosis other than desmoplastic medulloblastoma with no
                  evidence of CNS metastasis

               -  Medulloblastoma patients who are ≥3 and &lt; 5 yrs of age irrespective of histology
                  and with no evidence of CNS metastasis

          -  High-risk group:

               -  Any eligible histologic diagnosis with evidence of CNS metastasis

               -  Patients with extraneural metastasis are eligible for treatment on the high-risk
                  group

        PATIENT CHARACTERISTICS:

          -  Lansky performance status ≥ 30 (except for posterior fossa syndrome)

          -  WBC &gt; 2,000/mm3

          -  Platelets &gt; 50,000/mm3 (without support)

          -  Hemoglobin &gt; 8 g/dL (with or without support)

          -  ANC &gt; 500/mm3

          -  Serum creatinine &lt; 3 times upper limit of normal (ULN)

          -  ALT &lt; 5 times ULN

          -  Total bilirubin &lt; 3 times ULN

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No more than 31 days since prior definitive surgery

          -  No prior radiotherapy or chemotherapy other than corticosteroid therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amar Gajjar, MD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital at Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics of Minnesota - St. Paul</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lady Cilento Children's Hospital, Brisbane</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <link>
    <url>http://www.stjude.org/protocols</url>
    <description>Clinical Trials Open at St. Jude</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>January 10, 2008</study_first_submitted>
  <study_first_submitted_qc>January 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2008</study_first_posted>
  <results_first_submitted>September 26, 2018</results_first_submitted>
  <results_first_submitted_qc>January 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 30, 2019</results_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>untreated childhood medulloblastoma</keyword>
  <keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>untreated childhood pineoblastoma</keyword>
  <keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
  <keyword>childhood choroid plexus tumor</keyword>
  <keyword>childhood high grade glioma</keyword>
  <keyword>newly diagnosed childhood ependymoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 24, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT00602667/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>293 participants were enrolled between December 17, 2007 and April 19, 2017.</recruitment_details>
      <pre_assignment_details>Of the 293 participants enrolled, 3 were ineligible and removed from study, leaving 290 eligible patients. Eighty-one (81) of the 290 eligible patients enrolled had histologically confirmed medulloblastoma; medulloblastoma patients are the focus of the primary study objectives.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Low-Risk Group</title>
          <description>Patients with gross total resection (GTR)/no evidence of metastatic (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.</description>
        </group>
        <group group_id="P2">
          <title>Intermediate-Risk Group</title>
          <description>Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.</description>
        </group>
        <group group_id="P3">
          <title>High-Risk Group</title>
          <description>Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="156"/>
                <participants group_id="P3" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="75"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="63"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Still on Therapy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Family request</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Excessive toxicity</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Second malignancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive disease prior to therapy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants were patients with newly diagnosed tumors of the CNS, including medulloblastoma, supratentorial primitive neuroectodermal tumor (PNET), pineoblastoma, atypical teratoid rhabdoid tumor (ATRT), choroid plexus carcinoma, ependymoma, and high-grade glioma. All eligible patients enrolled were included in the baseline characteristics.</population>
      <group_list>
        <group group_id="B1">
          <title>Low-Risk Group</title>
          <description>Patients with gross total resection (GTR)/no evidence of metastatic (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.</description>
        </group>
        <group group_id="B2">
          <title>Intermediate-Risk Group</title>
          <description>Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.</description>
        </group>
        <group group_id="B3">
          <title>High-Risk Group</title>
          <description>Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
            <count group_id="B2" value="156"/>
            <count group_id="B3" value="77"/>
            <count group_id="B4" value="290"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.0" spread="10.0"/>
                    <measurement group_id="B2" value="22.9" spread="12.8"/>
                    <measurement group_id="B3" value="19.3" spread="10.4"/>
                    <measurement group_id="B4" value="20.8" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.1" lower_limit="0.2" upper_limit="35.2"/>
                    <measurement group_id="B2" value="21.9" lower_limit="1.8" upper_limit="60.6"/>
                    <measurement group_id="B3" value="20.0" lower_limit="0.9" upper_limit="36.9"/>
                    <measurement group_id="B4" value="20.1" lower_limit="0.2" upper_limit="60.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="131"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <category_list>
                <category>
                  <title>Mexican/Chicano</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NOS Spanish, Hispanic, Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non Spanish speaking, Non Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="231"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Puerto Rican</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>South or Central American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>American Indian/Alaskan/White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian/Alaskan Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian and White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black and White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multiple Race (NOS)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Probability of Progression-free Survival (PFS) for Medulloblastoma Patients</title>
        <description>Progression was defined as 25% increase in the size of any measurable lesion; the appearance of a new lesion; or the conversion of negative cerebrospinal fluid (CSF) cytology to positive. Defined as the time interval from date on treatment until the date of first progression, medulloblastoma-related death or date of last contact for patients who have not experienced an event. All eligible medulloblastoma patients who received any methotrexate are included in this analysis.</description>
        <time_frame>From date on treatment until date of first progression or relapse or disease related death or date of last contact, estimated at 1 year after treatment</time_frame>
        <population>All eligible medulloblastoma patients started methotrexate and were included (n=81). PFS estimates are reported by risk group.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Medulloblastoma patients &lt;3 years of age; histological diagnosis of desmoplastic nodular (DN)/medulloblastoma with extensive nodularity (MBEN); no evidence of metastatic disease (M0); and a surgical gross total resection (GTR) or near total resection (NTR) defined as residual tumor or imaging abnormality (not definite for residual tumor) with a size of less than 1 cm^2 on post-op computed tomography (CT) or magnetic resonance imaging (MRI) [R0])</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Medulloblastoma patients &lt;3 years of age, M0, and either R0 resection with any other medullo histology other than DN/MBEN (i.e., classic or large cell anaplastic (LCA)), or with a subtotal resection (with a residual tumor or imaging abnormality with a size of &gt;1 cm^2 on post-op imaging (R+), and DN/MBEN). Children 3-5 years of age were also included in this group High Risk</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Medulloblastoma patients &lt;3 years of age with evidence of metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Probability of Progression-free Survival (PFS) for Medulloblastoma Patients</title>
          <description>Progression was defined as 25% increase in the size of any measurable lesion; the appearance of a new lesion; or the conversion of negative cerebrospinal fluid (CSF) cytology to positive. Defined as the time interval from date on treatment until the date of first progression, medulloblastoma-related death or date of last contact for patients who have not experienced an event. All eligible medulloblastoma patients who received any methotrexate are included in this analysis.</description>
          <population>All eligible medulloblastoma patients started methotrexate and were included (n=81). PFS estimates are reported by risk group.</population>
          <units>Percent Probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9" lower_limit="56.5" upper_limit="91.3"/>
                    <measurement group_id="O2" value="46.9" lower_limit="30.2" upper_limit="63.6"/>
                    <measurement group_id="O3" value="30.8" lower_limit="14.1" upper_limit="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Probability of Progression-free Survival (PFS) for Medulloblastoma Patients by DNA Methylation Subgroup</title>
        <description>Defined as the time interval from date on treatment until the date of first progression, medulloblastoma-related death or date of last contact for patients who have not experienced an event. Eligible medulloblastoma patients who received any methotrexate and had molecularly confirmed medulloblastoma are included in this analysis. Five patients were excluded as 3 had no archival tissue available and 2 were found to not be medulloblastoma by methylation profile.</description>
        <time_frame>From date on treatment to date of first progression or relapse or disease related death or date of last contact, estimated at 1 year after treatment</time_frame>
        <population>Eligible patients with molecularly confirmed medulloblastoma (n=76) were included. PFS estimates are reported by methylation subgroup and risk group. There were no low-risk group 3 or group 4 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-risk SHH Patients</title>
            <description>Sonic hedgehog (SHH) medulloblastoma subgroup patients in the low-risk group</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-risk SHH Patients</title>
            <description>Sonic hedgehog (SHH) medulloblastoma subgroup patients in the intermediate-risk group</description>
          </group>
          <group group_id="O3">
            <title>High-risk SHH Patients</title>
            <description>Sonic hedgehog (SHH) medulloblastoma subgroup patients in the high-risk group</description>
          </group>
          <group group_id="O4">
            <title>Low-risk Group 3 Patients</title>
            <description>Group 3 (G3) medulloblastoma subgroup patients in the low-risk group</description>
          </group>
          <group group_id="O5">
            <title>Intermediate-risk Group 3 Patients</title>
            <description>Group 3 medulloblastoma subgroup patients in the intermediate-risk group</description>
          </group>
          <group group_id="O6">
            <title>High-risk Group 3 Patients</title>
            <description>Group 3 medulloblastoma subgroup patients in the high-risk group</description>
          </group>
          <group group_id="O7">
            <title>Low-risk Group 4 Patients</title>
            <description>Group 4 (G4) medulloblastoma subgroup patients in the low-risk group</description>
          </group>
          <group group_id="O8">
            <title>Intermediate-risk Group 4 Patients</title>
            <description>Group 4 (G4) medulloblastoma subgroup patients in the intermediate-risk group</description>
          </group>
          <group group_id="O9">
            <title>High-risk Group 4 Patients</title>
            <description>Group 4 medulloblastoma subgroup patients in the high-risk group</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Probability of Progression-free Survival (PFS) for Medulloblastoma Patients by DNA Methylation Subgroup</title>
          <description>Defined as the time interval from date on treatment until the date of first progression, medulloblastoma-related death or date of last contact for patients who have not experienced an event. Eligible medulloblastoma patients who received any methotrexate and had molecularly confirmed medulloblastoma are included in this analysis. Five patients were excluded as 3 had no archival tissue available and 2 were found to not be medulloblastoma by methylation profile.</description>
          <population>Eligible patients with molecularly confirmed medulloblastoma (n=76) were included. PFS estimates are reported by methylation subgroup and risk group. There were no low-risk group 3 or group 4 patients.</population>
          <units>Percent Probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9" lower_limit="56.5" upper_limit="91.3"/>
                    <measurement group_id="O2" value="50.0" lower_limit="19.0" upper_limit="81.0"/>
                    <measurement group_id="O3" value="54.5" lower_limit="27.3" upper_limit="81.7"/>
                    <measurement group_id="O5" value="30.8" lower_limit="8.5" upper_limit="53.1"/>
                    <measurement group_id="O6" value="9.1" lower_limit="0.0" upper_limit="21.1"/>
                    <measurement group_id="O8" value="62.5" lower_limit="31.9" upper_limit="93.1"/>
                    <measurement group_id="O9" value="50.0" lower_limit="1.0" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Probability of Event-free Survival (EFS) for Medulloblastoma Patients</title>
        <description>Defined as the time interval from date on treatment until the date of first progression, second malignancy or death due to any cause; or date of last contact for patients who have not experienced an event. All eligible medulloblastoma patients who received any methotrexate are included in this analysis.</description>
        <time_frame>From date on treatment to date of first progression, relapse, second malignancy or death from any cause or to date of last contact, estimated at 1 year after</time_frame>
        <population>Eligible medulloblastoma patients (n=81) were included. EFS estimates are reported by risk group.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Medulloblastoma patients &lt;3 years of age; histological diagnosis of desmoplastic nodular (DN)/medulloblastoma with extensive nodularity (MBEN); no evidence of metastatic disease (M0); and a surgical gross total resection (GTR) or near total resection (NTR) defined as residual tumor or imaging abnormality (not definite for residual tumor) with a size of less than 1 cm^2 on post-op computed tomography (CT) or magnetic resonance imaging (MRI) [R0])</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Medulloblastoma patients &lt;3 years of age, M0, and either R0 resection with any other medullo histology other than DN/MBEN (i.e., classic or large cell anaplastic (LCA)), or with a subtotal resection (with a residual tumor or imaging abnormality with a size of &gt;1 cm^2 on post-op imaging (R+), and DN/MBEN). Children 3-5 years of age were also included in this group High Risk</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Medulloblastoma patients &lt;3 years of age with evidence of metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Probability of Event-free Survival (EFS) for Medulloblastoma Patients</title>
          <description>Defined as the time interval from date on treatment until the date of first progression, second malignancy or death due to any cause; or date of last contact for patients who have not experienced an event. All eligible medulloblastoma patients who received any methotrexate are included in this analysis.</description>
          <population>Eligible medulloblastoma patients (n=81) were included. EFS estimates are reported by risk group.</population>
          <units>Percent Probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9" lower_limit="56.5" upper_limit="91.3"/>
                    <measurement group_id="O2" value="46.9" lower_limit="30.2" upper_limit="63.6"/>
                    <measurement group_id="O3" value="30.8" lower_limit="14.1" upper_limit="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Chromosomal Abnormalities</title>
        <description>Amplifications and deletions (gains and losses) for chromosomes of interest are shown in the table of measured values.</description>
        <time_frame>Based on samples obtained at the time of initial surgery or repeat surgery prior to treatment</time_frame>
        <population>Eligible medulloblastoma patients (n=81) were included in these analyses. 23 of 23 low risk patients had data available for this objective, as did 27/32 and 24/26 intermediate and high risk patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Medulloblastoma patients &lt;3 years of age; histological diagnosis of desmoplastic nodular (DN)/medulloblastoma with extensive nodularity (MBEN); no evidence of metastatic disease (M0); and a surgical gross total resection (GTR) or near total resection (NTR) defined as residual tumor or imaging abnormality (not definite for residual tumor) with a size of less than 1 cm^2 on post-op computed tomography (CT) or magnetic resonance imaging (MRI) [R0])</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Medulloblastoma patients &lt;3 years of age, M0, and either R0 resection with any other medullo histology other than DN/MBEN (i.e., classic or large cell anaplastic (LCA)), or with a subtotal resection (with a residual tumor or imaging abnormality with a size of &gt;1 cm^2 on post-op imaging (R+), and DN/MBEN). Children 3-5 years of age were also included in this group High Risk</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Medulloblastoma patients &lt;3 years of age with evidence of metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Chromosomal Abnormalities</title>
          <description>Amplifications and deletions (gains and losses) for chromosomes of interest are shown in the table of measured values.</description>
          <population>Eligible medulloblastoma patients (n=81) were included in these analyses. 23 of 23 low risk patients had data available for this objective, as did 27/32 and 24/26 intermediate and high risk patients.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>chr2p gain/amplification</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr2p loss/deletion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr2q gain/amplification</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr2q loss/deletion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr6p gain/amplification</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr6p loss/deletion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr6q gain/amplification</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr6q loss/deletion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr8p gain/amplification</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr8p loss/deletion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr8q gain/amplification</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr8q loss/deletion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr9p gain/amplification</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr9p loss/deletion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr9q gain/amplification</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr9q loss/deletion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr10p gain/amplification</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr10p loss/deletion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr10q gain/amplification</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr10q loss/deletion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr20p gain/amplification</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr20p loss/deletion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr20q gain/amplification</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr20q loss/deletion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numbers of Patients With Gene Alterations</title>
        <description>Gene alterations, which include single nucleotide variants (SNPs), amplifications, deletions, translocations, indels, and germline alterations are shown for specific genes of interest in the results table.</description>
        <time_frame>Based on samples obtained at the time of initial surgery or repeat surgery prior to treatment</time_frame>
        <population>Eligible medulloblastoma patients (n=81) were included in these analyses. Not all patients had data available for each gene.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Medulloblastoma patients &lt;3 years of age; histological diagnosis of desmoplastic nodular (DN)/medulloblastoma with extensive nodularity (MBEN); no evidence of metastatic disease (M0); and a surgical gross total resection (GTR) or near total resection (NTR) defined as residual tumor or imaging abnormality (not definite for residual tumor) with a size of less than 1 cm^2 on post-op computed tomography (CT) or magnetic resonance imaging (MRI) [R0])</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Medulloblastoma patients &lt;3 years of age, M0, and either R0 resection with any other medullo histology other than DN/MBEN (i.e., classic or large cell anaplastic (LCA)), or with a subtotal resection (with a residual tumor or imaging abnormality with a size of &gt;1 cm^2 on post-op imaging (R+), and DN/MBEN). Children 3-5 years of age were also included in this group High Risk</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Medulloblastoma patients &lt;3 years of age with evidence of metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers of Patients With Gene Alterations</title>
          <description>Gene alterations, which include single nucleotide variants (SNPs), amplifications, deletions, translocations, indels, and germline alterations are shown for specific genes of interest in the results table.</description>
          <population>Eligible medulloblastoma patients (n=81) were included in these analyses. Not all patients had data available for each gene.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PTCH1 alteration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUFU alteration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KMT2D alteration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMO alteration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCOR alteration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTEN alteration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRCA2 alteration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GLI2 alteration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMARCA4 alteration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TP53 alteration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MYCN alteration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numbers of Patients With Molecular Abnormalities by Tumor Type</title>
        <description>Alterations included single nucleotide variants (SNPs), amplifications, deletions, translocations, indels, and germline alterations. Cytogenetic information shows gains and losses as specified in the table of measured values.</description>
        <time_frame>Based on samples obtained at the time of initial surgery or repeat surgery prior to treatment</time_frame>
        <population>Eligible patients with molecularly confirmed medulloblastoma (n=76) were included in these analyses. Not all patients had data available for each gene.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-risk SHH Patients</title>
            <description>Sonic hedgehog (SHH) medulloblastoma subgroup patients in the low-risk group</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-risk SHH Patients</title>
            <description>Sonic hedgehog (SHH) medulloblastoma subgroup patients in the intermediate-risk group</description>
          </group>
          <group group_id="O3">
            <title>High-risk SHH Patients</title>
            <description>Sonic hedgehog (SHH) medulloblastoma subgroup patients in the high-risk group</description>
          </group>
          <group group_id="O4">
            <title>Low-risk Group 3 Patients</title>
            <description>Group 3 (G3) medulloblastoma subgroup patients in the low-risk group</description>
          </group>
          <group group_id="O5">
            <title>Intermediate-risk Group 3 Patients</title>
            <description>Group 3 medulloblastoma subgroup patients in the intermediate-risk group</description>
          </group>
          <group group_id="O6">
            <title>High-risk Group 3 Patients</title>
            <description>Group 3 medulloblastoma subgroup patients in the high-risk group</description>
          </group>
          <group group_id="O7">
            <title>Low-risk Group 4 Patients</title>
            <description>Group 4 (G4) medulloblastoma subgroup patients in the low-risk group</description>
          </group>
          <group group_id="O8">
            <title>Intermediate-risk Group 4 Patients</title>
            <description>Group 4 (G4) medulloblastoma subgroup patients in the intermediate-risk group</description>
          </group>
          <group group_id="O9">
            <title>High-risk Group 4 Patients</title>
            <description>Group 4 medulloblastoma subgroup patients in the high-risk group</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers of Patients With Molecular Abnormalities by Tumor Type</title>
          <description>Alterations included single nucleotide variants (SNPs), amplifications, deletions, translocations, indels, and germline alterations. Cytogenetic information shows gains and losses as specified in the table of measured values.</description>
          <population>Eligible patients with molecularly confirmed medulloblastoma (n=76) were included in these analyses. Not all patients had data available for each gene.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PTCH1 alteration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="8"/>
                    <count group_id="O9" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUFU alteration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="8"/>
                    <count group_id="O9" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KMT2D alteration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="5"/>
                    <count group_id="O9" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMO alteration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="5"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCOR alteration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="5"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTEN alteration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="8"/>
                    <count group_id="O9" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRCA2 alteration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="5"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GLI2 alteration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="7"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMARCA4 alteration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="5"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TP53 alteration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="8"/>
                    <count group_id="O9" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MYCN amplification</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="8"/>
                    <count group_id="O9" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr2p gain/amplification</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="7"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr2p loss/deletion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="7"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr2q gain/amplification</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="7"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr2q loss/deletion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="7"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr6p gain/amplification</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="7"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr6p loss/deletion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="7"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr6q gain/amplification</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="7"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr6q loss/deletion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="7"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr8p gain/amplification</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="7"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr8p loss/deletion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="7"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr8q gain/amplification</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="7"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr8q loss/deletion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="7"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr9p gain/amplification</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="7"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr9p loss/deletion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="7"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr9q gain/amplification</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="7"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr9q loss/deletion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="7"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr10p gain/amplification</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="7"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr10p loss/deletion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="7"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr10q gain/amplification</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="7"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr10q loss/deletion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="7"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr20p gain/amplification</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="7"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr20p loss/deletion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="7"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr20q gain/amplification</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="7"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chr20q loss/deletion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="7"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Successful Collections for Frozen and Fixed Tumor Samples</title>
        <description>Successful collections will be defined as the number of patients who have frozen/fixed tumor samples available.</description>
        <time_frame>Based on samples obtained at the time of initial surgery or repeat surgery prior to treatment</time_frame>
        <population>All eligible patients enrolled (n=290) were included in this analysis. The numbers of patients with pre-study samples were considered for these results.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with (M0) medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Successful Collections for Frozen and Fixed Tumor Samples</title>
          <description>Successful collections will be defined as the number of patients who have frozen/fixed tumor samples available.</description>
          <population>All eligible patients enrolled (n=290) were included in this analysis. The numbers of patients with pre-study samples were considered for these results.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number with frozen tumor tissue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number with fixed tumor tissue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="153"/>
                    <measurement group_id="O3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event-free Survival (EFS) Compared to Historical Controls</title>
        <description>EFS was measured from the date of initial treatment to the earliest date of disease progression, second malignancy or death for patients who fail; and to the date of last contact for patients who remain at risk for failure. 1-year EFS estimates are reported by risk group. EFS was compared to St. Jude historical cohorts by risk group using hazard ratios with 95% confidence intervals.</description>
        <time_frame>From date on treatment until date of first event (progression, second malignancy or death) or until date of last contact, assessed up to 10 years</time_frame>
        <population>Eligible medulloblastoma patients who received any methotrexate were included in this analysis. Hazard ratios with 95% confidence intervals are reported and compare SJYC07 patients to historical controls in each risk group. As there were too few low-risk historical controls, no hazard ratio is included for the low-risk group.</population>
        <group_list>
          <group group_id="O1">
            <title>SJYC07 Low-risk Medulloblastoma Patients</title>
            <description>Medulloblastoma patients &lt;3 years of age; histological diagnosis of desmoplastic nodular (DN)/medulloblastoma with extensive nodularity (MBEN); no evidence of metastatic disease (M0); and a surgical gross total resection (GTR) or near total resection (NTR) defined as residual tumor or imaging abnormality (not definite for residual tumor) with a size of less than 1 cm^2 on post-op computed tomography (CT) or magnetic resonance imaging (MRI) [R0])</description>
          </group>
          <group group_id="O2">
            <title>SJYC07 Intermediate-risk Medulloblastoma Patients</title>
            <description>SJYC07 medulloblastoma patients &lt;3 years of age, no evidence of metastatic disease (M0), and either R0 resection with any other medullo histology other than histological diagnosis of desmoplastic nodular (DN)/medulloblastoma with extensive nodularity (MBEN) (i.e., classic or large cell anaplastic (LCA)), or with a subtotal resection (with a residual tumor or imaging abnormality with a size of &gt;1 cm^2 on post-op imaging (R+), and DN/MBEN). Children 3-5 years of age were also included in this group</description>
          </group>
          <group group_id="O3">
            <title>SJYC07 High-risk Medulloblastoma Patients</title>
            <description>SJYC07 medulloblastoma patients &lt;3 years of age with evidence of metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Event-free Survival (EFS) Compared to Historical Controls</title>
          <description>EFS was measured from the date of initial treatment to the earliest date of disease progression, second malignancy or death for patients who fail; and to the date of last contact for patients who remain at risk for failure. 1-year EFS estimates are reported by risk group. EFS was compared to St. Jude historical cohorts by risk group using hazard ratios with 95% confidence intervals.</description>
          <population>Eligible medulloblastoma patients who received any methotrexate were included in this analysis. Hazard ratios with 95% confidence intervals are reported and compare SJYC07 patients to historical controls in each risk group. As there were too few low-risk historical controls, no hazard ratio is included for the low-risk group.</population>
          <units>Percent probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9" lower_limit="56.5" upper_limit="91.3"/>
                    <measurement group_id="O2" value="46.9" lower_limit="30.2" upper_limit="63.6"/>
                    <measurement group_id="O3" value="30.8" lower_limit="14.1" upper_limit="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The historical control included 10 medulloblastoma patients treated during 1998-2006 who would have been classified as intermediate risk according to SJYC07 criteria (section 13.1.3 of protocol).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>4.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.17</ci_lower_limit>
            <ci_upper_limit>21.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The historical control included 14 medulloblastoma patients treated during 1998-2006 who would have been classified as high risk according to SJYC07 criteria (section 13.1.3 of protocol).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>1.84</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) Compared to Historical Controls</title>
        <description>OS was measured from the date of initial treatment to date of death or to date of last contact for survivors. 1-year OS estimates were reported by risk group. OS was compared to St. Jude historical cohorts by risk group using hazard ratios with 95% confidence intervals.</description>
        <time_frame>1 year after treatment initiation of last patient</time_frame>
        <population>Eligible medulloblastoma patients who received any methotrexate were included in this analysis. Hazard ratios with 95% confidence intervals are reported and compare SJYC07 patients to historical controls in each risk group. As there were too few low-risk historical controls, no hazard ratio is included for the low-risk group.</population>
        <group_list>
          <group group_id="O1">
            <title>SJYC07 Low-risk Medulloblastoma Patients</title>
            <description>Medulloblastoma patients &lt;3 years of age; histological diagnosis of desmoplastic nodular (DN)/medulloblastoma with extensive nodularity (MBEN); no evidence of metastatic disease (M0); and a surgical gross total resection (GTR) or near total resection (NTR) defined as residual tumor or imaging abnormality (not definite for residual tumor) with a size of less than 1 cm^2 on post-op computed tomography (CT) or magnetic resonance imaging (MRI) [R0])</description>
          </group>
          <group group_id="O2">
            <title>SJYC07 Intermediate-risk Medulloblastoma Patients</title>
            <description>SJYC07 medulloblastoma patients &lt;3 years of age, no evidence of metastatic disease (M0), and either R0 resection with any other medullo histology other than histological diagnosis of desmoplastic nodular (DN)/medulloblastoma with extensive nodularity (MBEN) (i.e., classic or large cell anaplastic (LCA)), or with a subtotal resection (with a residual tumor or imaging abnormality with a size of &gt;1 cm^2 on post-op imaging (R+), and DN/MBEN). Children 3-5 years of age were also included in this group</description>
          </group>
          <group group_id="O3">
            <title>SJYC07 High-risk Medulloblastoma Patients</title>
            <description>SJYC07 medulloblastoma patients &lt;3 years of age with evidence of metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) Compared to Historical Controls</title>
          <description>OS was measured from the date of initial treatment to date of death or to date of last contact for survivors. 1-year OS estimates were reported by risk group. OS was compared to St. Jude historical cohorts by risk group using hazard ratios with 95% confidence intervals.</description>
          <population>Eligible medulloblastoma patients who received any methotrexate were included in this analysis. Hazard ratios with 95% confidence intervals are reported and compare SJYC07 patients to historical controls in each risk group. As there were too few low-risk historical controls, no hazard ratio is included for the low-risk group.</population>
          <units>Percent probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="100"/>
                    <measurement group_id="O2" value="84.4" lower_limit="72.1" upper_limit="96.7"/>
                    <measurement group_id="O3" value="61.5" lower_limit="43.9" upper_limit="79.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The historical control included 10 medulloblastoma patients treated during 1998-2006 who would have been classified as intermediate risk according to SJYC07 criteria (section 13.1.3 of protocol).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>8.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The historical control included 14 medulloblastoma patients treated during 1998-2006 who would have been classified as high risk according to SJYC07 criteria (section 13.1.3 of protocol).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Objective Responses Rate to Induction Chemotherapy</title>
        <description>For patients treated in the intermediate and high risk strata with residual or metastatic disease we will estimate the stratum-specific objective response rate (complete response (CR) or partial response [ PR]). All patients who receive at least 1 -dose of methotrexate are evaluable for response. Objective responses must be sustained for at least eight weeks.</description>
        <time_frame>From on-study date to 2 months after completion of induction chemotherapy (up to 4 months after on-study date)</time_frame>
        <population>Eligible intermediate and high risk group patients who received at least 1 dose of methotrexate were included in this analysis. One of the high risk patients did not start therapy and was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O2">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Objective Responses Rate to Induction Chemotherapy</title>
          <description>For patients treated in the intermediate and high risk strata with residual or metastatic disease we will estimate the stratum-specific objective response rate (complete response (CR) or partial response [ PR]). All patients who receive at least 1 -dose of methotrexate are evaluable for response. Objective responses must be sustained for at least eight weeks.</description>
          <population>Eligible intermediate and high risk group patients who received at least 1 dose of methotrexate were included in this analysis. One of the high risk patients did not start therapy and was excluded.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.3" lower_limit="50.2" upper_limit="66.2"/>
                    <measurement group_id="O2" value="21.1" lower_limit="12.5" upper_limit="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Feasibility and Toxicity of Administering Vinblastine With Induction Chemotherapy for Patients With Metastatic Disease as Measured by the Percentage of Courses Delayed for More Than 7 Days Due to Toxicity</title>
        <description>For the subset of patients with metastatic disease (high-risk group patients), during induction, the proportion percentage of courses during which subsequent chemotherapy administration was delayed for more than 7 days due to toxicity will be calculated. Patients were to receive 4 courses of induction and then consolidation chemotherapy.</description>
        <time_frame>From on-study date up to 4 months after on-study date</time_frame>
        <population>Eligible high-risk group patients who started therapy were included in this analysis (n=76). 1 patient enrolled on the high-risk arm did not start therapy due to early disease progression and was excluded. Courses 2-4 of induction and the 1st consolidation course were used in this analysis. 76 patients (with 263 courses) were included.</population>
        <group_list>
          <group group_id="O1">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility and Toxicity of Administering Vinblastine With Induction Chemotherapy for Patients With Metastatic Disease as Measured by the Percentage of Courses Delayed for More Than 7 Days Due to Toxicity</title>
          <description>For the subset of patients with metastatic disease (high-risk group patients), during induction, the proportion percentage of courses during which subsequent chemotherapy administration was delayed for more than 7 days due to toxicity will be calculated. Patients were to receive 4 courses of induction and then consolidation chemotherapy.</description>
          <population>Eligible high-risk group patients who started therapy were included in this analysis (n=76). 1 patient enrolled on the high-risk arm did not start therapy due to early disease progression and was excluded. Courses 2-4 of induction and the 1st consolidation course were used in this analysis. 76 patients (with 263 courses) were included.</population>
          <units>Percentage of courses delayed</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>courses</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>courses</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="1.8" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Feasibility and Toxicity of Administering Consolidation Therapy Including Cyclophosphamide and Pharmacokinetically Targeted Topotecan to Patients With Metastatic Disease Based on the Percentage of Courses Delayed for More Than 7 Days Due to Toxicity</title>
        <description>For the subset of patients with metastatic disease (high-risk group patients), during consolidation, we will calculate the number and proportion of courses during which subsequent chemotherapy administration was delayed for more than 7 days due to toxicity. Patients were to received 2 courses of consolidation chemotherapy and then maintenance therapy.</description>
        <time_frame>At completion of consolidation therapy (up to 6 months after on-study date)</time_frame>
        <population>Eligible high-risk group patients who started therapy were included. Course 2 of consolidation and the 1st course of maintenance were used in this analysis and assessed for delays &gt;7 days due to toxicity. Of the 76 high-risk patients that started induction therapy, 50 started consolidation (with 47 courses included in this analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility and Toxicity of Administering Consolidation Therapy Including Cyclophosphamide and Pharmacokinetically Targeted Topotecan to Patients With Metastatic Disease Based on the Percentage of Courses Delayed for More Than 7 Days Due to Toxicity</title>
          <description>For the subset of patients with metastatic disease (high-risk group patients), during consolidation, we will calculate the number and proportion of courses during which subsequent chemotherapy administration was delayed for more than 7 days due to toxicity. Patients were to received 2 courses of consolidation chemotherapy and then maintenance therapy.</description>
          <population>Eligible high-risk group patients who started therapy were included. Course 2 of consolidation and the 1st course of maintenance were used in this analysis and assessed for delays &gt;7 days due to toxicity. Of the 76 high-risk patients that started induction therapy, 50 started consolidation (with 47 courses included in this analysis).</population>
          <units>Percentage of courses delayed</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>courses</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>courses</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0.5" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients With Sustained Objective Responses Rate After Consolidation</title>
        <description>For patients enrolled on the high-risk arm with measurable residual disease after induction treated with consolidation therapy, we will estimate the objective response (complete response (CR)/partial response (PR)) rate after consolidation therapy with a 95% confidence interval. Objective responses must be sustained for at least eight weeks. All patients who receive at least 1 dose of cyclophosphamide or topotecan during consolidation are evaluable for response.</description>
        <time_frame>8 weeks after completion of consolidation therapy (up to 8 months after on-study date)</time_frame>
        <population>Of the 50 high-risk patients that started consolidation chemotherapy, 38 had measurable residual disease after induction and were included in this result.</population>
        <group_list>
          <group group_id="O1">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients With Sustained Objective Responses Rate After Consolidation</title>
          <description>For patients enrolled on the high-risk arm with measurable residual disease after induction treated with consolidation therapy, we will estimate the objective response (complete response (CR)/partial response (PR)) rate after consolidation therapy with a 95% confidence interval. Objective responses must be sustained for at least eight weeks. All patients who receive at least 1 dose of cyclophosphamide or topotecan during consolidation are evaluable for response.</description>
          <population>Of the 50 high-risk patients that started consolidation chemotherapy, 38 had measurable residual disease after induction and were included in this result.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" lower_limit="4.4" upper_limit="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Feasibility and Toxicity of Administering Oral Maintenance Therapy in Children &lt;3 Years of Age as Measured by the Percentage of Total Scheduled Maintenance Doses Received</title>
        <description>These data are based on patient diaries. For children &lt;3 years of age, we will calculate the percentage of total scheduled doses each patient received per course for each of the oral maintenance courses and report the overall average number percentage of doses received per course across patients. If patients received all planned doses, their percentage would be 100%. If the average percentage was less than 75%, then feasibility would be in question.</description>
        <time_frame>From start of oral maintenance therapy (approximately 6 months after on-study date) to completion of oral maintenance therapy (up to 1 year after on-study date)</time_frame>
        <population>Eligible patients less than 3 years of age (n=273) constituted the study population for this analysis; 167 of these patients started the first course of maintenance and were included in this analysis (50 low-risk, 87 intermediate-risk, and 30 high-risk patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients &lt;3 years of age with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients &lt;3 years of age with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients &lt;3 years of age with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility and Toxicity of Administering Oral Maintenance Therapy in Children &lt;3 Years of Age as Measured by the Percentage of Total Scheduled Maintenance Doses Received</title>
          <description>These data are based on patient diaries. For children &lt;3 years of age, we will calculate the percentage of total scheduled doses each patient received per course for each of the oral maintenance courses and report the overall average number percentage of doses received per course across patients. If patients received all planned doses, their percentage would be 100%. If the average percentage was less than 75%, then feasibility would be in question.</description>
          <population>Eligible patients less than 3 years of age (n=273) constituted the study population for this analysis; 167 of these patients started the first course of maintenance and were included in this analysis (50 low-risk, 87 intermediate-risk, and 30 high-risk patients).</population>
          <units>Percentage of scheduled doses received</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" spread="8"/>
                    <measurement group_id="O2" value="91" spread="23"/>
                    <measurement group_id="O3" value="98" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Neurostructure, Especially White Matter Volume and Integrity</title>
        <description>Quantitative MRI measures of change in neurostructure (especially white matter volume and integrity) over time will be assessed using a random effects model incorporating various covariates. Covariates to be considered include age at diagnosis, time since diagnosis and risk-arm. Differences in quantitative MRI measures of neurostructure volume and integrity between patient groups will be evaluated as a metric of structural neurotoxicity of therapy.</description>
        <time_frame>From baseline to 60 months off therapy</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of PET Scans With Loss of Signal Intensity</title>
        <description>Measures will be analyzed for intermediate risk participants who receive proton beam therapy (PBT) and who consent. This objective aims to assess the feasibility of using post-proton beam therapy (PBT) positron emission tomography (PET) as an in-vivo dosimetric and distal edge verification system in this patient population. To quantify the decay in signal, 134 scans from 53 patients were analyzed by recording the mean activation value (MAV), the average recorded PET signal from activation, within the target volume. With each patient being given the same dose, the percent standard deviation in the MAV can serve as a quantitative representation of signal loss due to radioactive decay.</description>
        <time_frame>Up to 3 times during RT consolidation</time_frame>
        <population>Intermediate risk patients treated at St. Jude were eligible to receive proton beam therapy through referral to the University of Florida Proton Therapy Institute. Patients electing to receive PBT and post-treatment PET scans after the delivery of one treatment beam were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Intermediate Risk Group</title>
            <description>Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of PET Scans With Loss of Signal Intensity</title>
          <description>Measures will be analyzed for intermediate risk participants who receive proton beam therapy (PBT) and who consent. This objective aims to assess the feasibility of using post-proton beam therapy (PBT) positron emission tomography (PET) as an in-vivo dosimetric and distal edge verification system in this patient population. To quantify the decay in signal, 134 scans from 53 patients were analyzed by recording the mean activation value (MAV), the average recorded PET signal from activation, within the target volume. With each patient being given the same dose, the percent standard deviation in the MAV can serve as a quantitative representation of signal loss due to radioactive decay.</description>
          <population>Intermediate risk patients treated at St. Jude were eligible to receive proton beam therapy through referral to the University of Florida Proton Therapy Institute. Patients electing to receive PBT and post-treatment PET scans after the delivery of one treatment beam were included in the analysis.</population>
          <units>mean activation value (MAV)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Scans</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Scans</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Concentration of Cerebrospinal Fluid (CSF) Neurotransmitters</title>
        <time_frame>Baseline, at the completion of therapy, and every 12 months up to 36 months after off therapy date</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Neurocognitive Performance</title>
        <description>Age standardized performance on measures of global cognitive functioning, attention, processing speed and executive functions.</description>
        <time_frame>Baseline, at the completion of therapy, and every 12 months up to 60 months off therapy</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Type of Genetic Polymorphisms</title>
        <time_frame>At study enrollment (Day 0)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacogenetic Variation on CNS Transmitters</title>
        <time_frame>At study enrollment (Day 0)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Neuropsychological Performance</title>
        <description>The primary interest is in global cognitive functioning. This is measured using the SB-V Routing subtests.</description>
        <time_frame>Baseline, 6- and 12-months from treatment initiation, and yearly after the first year (up to 5 years)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quantitative Magnetic Resonance (MR) Measures in the Frontal Lobe</title>
        <time_frame>Baseline and up to 60 months after completion of therapy.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Neurocognitive Performance in Attention, Working Memory, and Fluency</title>
        <description>Neurocognitive performance is assessed using a comprehensive battery of standard tests. Sustained attention is measured using the TOVA; selective auditory attention is measured using the WJIII; nonverbal attention span is measured using the SB-V Block Span subset. Working memory is measured using the WJIII. Fluency is measured using is also measured using the WJIII.</description>
        <time_frame>Baseline and prior to cycle A1 (~6 months) and at end of therapy and at 12, 24, 36, 48 and 60 months after completion of therapy.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quantitative MR Measures in the Right Frontal-parietal Regions</title>
        <time_frame>Baseline and up to 5 years after completion of therapy</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Neurocognitive Performance in Visual-spatial Reasoning and Processing Speed</title>
        <description>Processing speed will be measured using the WJIII. Visual perception and visual-motor integration will be measured using the Beery VMI.</description>
        <time_frame>Baseline and up to 5 years after completion of therapy.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Endocrinopathy</title>
        <description>Serial GH testing (at baseline, the end of therapy, and at 6 and 24 months after completion of therapy) will be performed on consenting patients in order to estimate longitudinal change in GH secretion as measured by mean peak GH values, with the intent to explore associations with radiation dose to the hypothalamus. Since determination of proton- or photon-based radiotherapy is not based on randomization, it will not be possible to compare the endocrine outcome between the patients with and without PBT. However, the differences between these two clinical cohorts with respect to clinical and demographic variables of interest will be summarized via descriptive statistics.</description>
        <time_frame>Baseline, end of therapy, and at 6- and 24-months after completion of therapy</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Longitudinal Change in Growth Hormone Secretion</title>
        <description>The intent of this objective is to estimate the longitudinal change in abnormal GH secretion as measured by mean peak GH values via a mixed effects model for the patients who receive PBT.</description>
        <time_frame>Baseline, end of therapy, and at 6- and 24-months after completion of therapy</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Methotrexate Clearance in Induction Cycle 1</title>
        <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 1. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate clearance are obtained using post hoc analysis.</description>
        <time_frame>Pre-infusion and 6, 23, 42, 66 hours from start of Methotrexate (MTX)</time_frame>
        <population>Eligible patients who received methotrexate during induction cycle 1 and had samples collected for PK analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Methotrexate Clearance in Induction Cycle 1</title>
          <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 1. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate clearance are obtained using post hoc analysis.</description>
          <population>Eligible patients who received methotrexate during induction cycle 1 and had samples collected for PK analysis</population>
          <units>L/h/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.69" lower_limit="2.19" upper_limit="11.08"/>
                    <measurement group_id="O2" value="6.06" lower_limit="3.07" upper_limit="10.69"/>
                    <measurement group_id="O3" value="5.65" lower_limit="1.71" upper_limit="9.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Methotrexate Clearance in Induction Cycle 2</title>
        <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 2. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate clearance are obtained using post hoc analysis.</description>
        <time_frame>Pre-infusion and 6, 23, 42, 66 hours from start of MTX</time_frame>
        <population>Eligible patients who received methotrexate during induction cycle 2 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Methotrexate Clearance in Induction Cycle 2</title>
          <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 2. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate clearance are obtained using post hoc analysis.</description>
          <population>Eligible patients who received methotrexate during induction cycle 2 and had samples collected for PK analysis.</population>
          <units>L/h/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.47" lower_limit="2.43" upper_limit="10.56"/>
                    <measurement group_id="O2" value="5.70" lower_limit="2.71" upper_limit="8.98"/>
                    <measurement group_id="O3" value="5.70" lower_limit="2.78" upper_limit="8.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Methotrexate Clearance in Induction Cycle 3</title>
        <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 3. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate clearance are obtained using post hoc analysis.</description>
        <time_frame>Pre-infusion and 6, 23, 42, 66 hours from start of MTX</time_frame>
        <population>Eligible patients who received methotrexate during induction cycle 3 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Methotrexate Clearance in Induction Cycle 3</title>
          <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 3. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate clearance are obtained using post hoc analysis.</description>
          <population>Eligible patients who received methotrexate during induction cycle 3 and had samples collected for PK analysis.</population>
          <units>L/h/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.68" lower_limit="1.93" upper_limit="9.61"/>
                    <measurement group_id="O2" value="5.78" lower_limit="2.59" upper_limit="9.27"/>
                    <measurement group_id="O3" value="5.81" lower_limit="2.78" upper_limit="10.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Methotrexate Clearance in Induction Cycle 4</title>
        <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 4. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate clearance are obtained using post hoc analysis.</description>
        <time_frame>Pre-infusion and 6, 23, 42, 66 hours from start of MTX</time_frame>
        <population>Eligible patients who received methotrexate during induction cycle 4 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Methotrexate Clearance in Induction Cycle 4</title>
          <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 4. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate clearance are obtained using post hoc analysis.</description>
          <population>Eligible patients who received methotrexate during induction cycle 4 and had samples collected for PK analysis.</population>
          <units>L/h/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.75" lower_limit="2.14" upper_limit="9.65"/>
                    <measurement group_id="O2" value="5.89" lower_limit="2.95" upper_limit="8.84"/>
                    <measurement group_id="O3" value="5.79" lower_limit="2.36" upper_limit="9.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Methotrexate Volume of Central Compartment in Induction Cycle 1</title>
        <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 1. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate volume of central compartment are obtained using post hoc analysis.</description>
        <time_frame>Pre-infusion and 6, 23, 42, 66 hours from start of MTX</time_frame>
        <population>Eligible patients who received methotrexate during induction cycle 1 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Methotrexate Volume of Central Compartment in Induction Cycle 1</title>
          <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 1. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate volume of central compartment are obtained using post hoc analysis.</description>
          <population>Eligible patients who received methotrexate during induction cycle 1 and had samples collected for PK analysis.</population>
          <units>L/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.63" lower_limit="7.09" upper_limit="29.58"/>
                    <measurement group_id="O2" value="13.70" lower_limit="7.03" upper_limit="28.21"/>
                    <measurement group_id="O3" value="13.25" lower_limit="5.65" upper_limit="20.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Methotrexate Volume of Central Compartment in Induction Cycle 2</title>
        <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 2. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate volume of central compartment are obtained using post hoc analysis.</description>
        <time_frame>Pre-infusion and 6, 23, 42, 66 hours from start of MTX</time_frame>
        <population>Eligible patients who received methotrexate during induction cycle 2 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Methotrexate Volume of Central Compartment in Induction Cycle 2</title>
          <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 2. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate volume of central compartment are obtained using post hoc analysis.</description>
          <population>Eligible patients who received methotrexate during induction cycle 2 and had samples collected for PK analysis.</population>
          <units>L/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.77" lower_limit="5.88" upper_limit="28.19"/>
                    <measurement group_id="O2" value="13.73" lower_limit="6.47" upper_limit="31.45"/>
                    <measurement group_id="O3" value="13.62" lower_limit="6.87" upper_limit="22.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Methotrexate Volume of Central Compartment in Induction Cycle 3</title>
        <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 3. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate volume of central compartment are obtained using post hoc analysis.</description>
        <time_frame>Pre-infusion and 6, 23, 42, 66 hours from start of MTX</time_frame>
        <population>Eligible patients who received methotrexate during induction cycle 3 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Methotrexate Volume of Central Compartment in Induction Cycle 3</title>
          <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 3. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate volume of central compartment are obtained using post hoc analysis.</description>
          <population>Eligible patients who received methotrexate during induction cycle 3 and had samples collected for PK analysis.</population>
          <units>L/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.70" lower_limit="6.27" upper_limit="28.90"/>
                    <measurement group_id="O2" value="13.55" lower_limit="7.31" upper_limit="24.48"/>
                    <measurement group_id="O3" value="13.87" lower_limit="6.84" upper_limit="22.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Methotrexate Volume of Central Compartment in Induction Cycle 4</title>
        <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 4. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate volume of central compartment are obtained using post hoc analysis.</description>
        <time_frame>Pre-infusion and 6, 23, 42, 66 hours from start of MTX</time_frame>
        <population>Eligible patients who received methotrexate during induction cycle 4 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Methotrexate Volume of Central Compartment in Induction Cycle 4</title>
          <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 4. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate volume of central compartment are obtained using post hoc analysis.</description>
          <population>Eligible patients who received methotrexate during induction cycle 4 and had samples collected for PK analysis.</population>
          <units>L/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.64" lower_limit="7.16" upper_limit="22.92"/>
                    <measurement group_id="O2" value="13.31" lower_limit="7.93" upper_limit="21.51"/>
                    <measurement group_id="O3" value="13.68" lower_limit="6.94" upper_limit="21.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Methotrexate AUC0-66h in Induction Cycle 1</title>
        <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 1. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate AUC0-66h (area under concentration curve from time 0 to 66 hours post-dose) are obtained using post hoc analysis.</description>
        <time_frame>Pre-infusion and 6, 23, 42, 66 hours from start of MTX</time_frame>
        <population>Eligible patients who received methotrexate during induction cycle 1 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Methotrexate AUC0-66h in Induction Cycle 1</title>
          <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 1. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate AUC0-66h (area under concentration curve from time 0 to 66 hours post-dose) are obtained using post hoc analysis.</description>
          <population>Eligible patients who received methotrexate during induction cycle 1 and had samples collected for PK analysis.</population>
          <units>µmol·h/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1797" lower_limit="993" upper_limit="5029"/>
                    <measurement group_id="O2" value="1813" lower_limit="1029" upper_limit="3584"/>
                    <measurement group_id="O3" value="1821" lower_limit="1053" upper_limit="3631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Methotrexate AUC0-66h in Induction Cycle 2</title>
        <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 2. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate AUC0-66h (area under concentration curve from time 0 to 66 hours post-dose) are obtained using post hoc analysis.</description>
        <time_frame>Pre-infusion and 6, 23, 42, 66 hours from start of MTX</time_frame>
        <population>Eligible patients who received methotrexate during induction cycle 2 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Methotrexate AUC0-66h in Induction Cycle 2</title>
          <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 2. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate AUC0-66h (area under concentration curve from time 0 to 66 hours post-dose) are obtained using post hoc analysis.</description>
          <population>Eligible patients who received methotrexate during induction cycle 2 and had samples collected for PK analysis.</population>
          <units>µmol·h/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1900" lower_limit="1042" upper_limit="3267"/>
                    <measurement group_id="O2" value="1902" lower_limit="1225" upper_limit="3742"/>
                    <measurement group_id="O3" value="1879" lower_limit="1229" upper_limit="3271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Methotrexate AUC0-66h in Induction Cycle 3</title>
        <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 3. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate AUC0-66h (area under concentration curve from time 0 to 66 hours post-dose) are obtained using post hoc analysis.</description>
        <time_frame>Pre-infusion and 6, 23, 42, 66 hours from start of MTX</time_frame>
        <population>Eligible patients who received methotrexate during induction cycle 3 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Methotrexate AUC0-66h in Induction Cycle 3</title>
          <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 3. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate AUC0-66h (area under concentration curve from time 0 to 66 hours post-dose) are obtained using post hoc analysis.</description>
          <population>Eligible patients who received methotrexate during induction cycle 3 and had samples collected for PK analysis.</population>
          <units>µmol·h/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1872" lower_limit="1145" upper_limit="3501"/>
                    <measurement group_id="O2" value="1879" lower_limit="1187" upper_limit="3756"/>
                    <measurement group_id="O3" value="1831" lower_limit="979" upper_limit="3139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Methotrexate AUC0-66h in Induction Cycle 4</title>
        <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 4. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate AUC0-66h (area under concentration curve from time 0 to 66 hours post-dose) are obtained using post hoc analysis.</description>
        <time_frame>Pre-infusion and 6, 23, 42, 66 hours from start of MTX</time_frame>
        <population>Eligible patients who received methotrexate during induction cycle 4 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Methotrexate AUC0-66h in Induction Cycle 4</title>
          <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 4. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate AUC0-66h (area under concentration curve from time 0 to 66 hours post-dose) are obtained using post hoc analysis.</description>
          <population>Eligible patients who received methotrexate during induction cycle 4 and had samples collected for PK analysis.</population>
          <units>µmol·h/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1804" lower_limit="1141" upper_limit="3504"/>
                    <measurement group_id="O2" value="1841" lower_limit="1245" upper_limit="3727"/>
                    <measurement group_id="O3" value="1886" lower_limit="1219" upper_limit="3491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Methotrexate Concentration at 42 Hours Post-dose in Induction Cycle 1</title>
        <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 1. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate concentration at 42 hours post-dose are obtained using post hoc analysis.</description>
        <time_frame>42 hours from start of MTX</time_frame>
        <population>Eligible patients who received methotrexate during induction cycle 1 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Methotrexate Concentration at 42 Hours Post-dose in Induction Cycle 1</title>
          <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 1. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate concentration at 42 hours post-dose are obtained using post hoc analysis.</description>
          <population>Eligible patients who received methotrexate during induction cycle 1 and had samples collected for PK analysis.</population>
          <units>µmol/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" lower_limit="0.22" upper_limit="3.68"/>
                    <measurement group_id="O2" value="0.57" lower_limit="0.15" upper_limit="4.61"/>
                    <measurement group_id="O3" value="0.61" lower_limit="0.14" upper_limit="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Methotrexate Concentration at 42 Hours Post-dose in Induction Cycle 2</title>
        <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 2. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate concentration at 42 hours post-dose are obtained using post hoc analysis.</description>
        <time_frame>42 hours from start of MTX</time_frame>
        <population>Eligible patients who received methotrexate during induction cycle 2 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Methotrexate Concentration at 42 Hours Post-dose in Induction Cycle 2</title>
          <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 2. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate concentration at 42 hours post-dose are obtained using post hoc analysis.</description>
          <population>Eligible patients who received methotrexate during induction cycle 2 and had samples collected for PK analysis.</population>
          <units>µmol/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" lower_limit="0.19" upper_limit="3.09"/>
                    <measurement group_id="O2" value="0.72" lower_limit="0.26" upper_limit="7.61"/>
                    <measurement group_id="O3" value="0.69" lower_limit="0.24" upper_limit="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Methotrexate Concentration at 42 Hours Post-dose in Induction Cycle 3</title>
        <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 3. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate concentration at 42 hours post-dose are obtained using post hoc analysis.</description>
        <time_frame>42 hours from start of MTX</time_frame>
        <population>Eligible patients who received methotrexate during induction cycle 3 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Methotrexate Concentration at 42 Hours Post-dose in Induction Cycle 3</title>
          <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 3. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate concentration at 42 hours post-dose are obtained using post hoc analysis.</description>
          <population>Eligible patients who received methotrexate during induction cycle 3 and had samples collected for PK analysis.</population>
          <units>µmol/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" lower_limit="0.20" upper_limit="2.88"/>
                    <measurement group_id="O2" value="0.70" lower_limit="0.16" upper_limit="4.34"/>
                    <measurement group_id="O3" value="0.58" lower_limit="0.24" upper_limit="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Methotrexate Concentration at 42 Hours Post-dose in Induction Cycle 4</title>
        <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 4. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate concentration at 42 hours post-dose are obtained using post hoc analysis.</description>
        <time_frame>42 hours from start of MTX</time_frame>
        <population>Eligible patients who received methotrexate during induction cycle 4 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Methotrexate Concentration at 42 Hours Post-dose in Induction Cycle 4</title>
          <description>Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 4. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate concentration at 42 hours post-dose are obtained using post hoc analysis.</description>
          <population>Eligible patients who received methotrexate during induction cycle 4 and had samples collected for PK analysis.</population>
          <units>µmol/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" lower_limit="0.26" upper_limit="3.12"/>
                    <measurement group_id="O2" value="0.64" lower_limit="0.22" upper_limit="3.22"/>
                    <measurement group_id="O3" value="0.55" lower_limit="0.20" upper_limit="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cyclophosphamide Clearance in Induction Chemotherapy</title>
        <description>Cyclophosphamide plasma concentration-time data are collected on day 9 in one cycle of induction chemotherapy. Individual estimates of cyclophosphamide clearance are obtained using post hoc analysis.</description>
        <time_frame>Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion</time_frame>
        <population>Eligible patients who received cyclophosphamide during a cycle of induction therapy and had samples collected for PK analysis..</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Cyclophosphamide Clearance in Induction Chemotherapy</title>
          <description>Cyclophosphamide plasma concentration-time data are collected on day 9 in one cycle of induction chemotherapy. Individual estimates of cyclophosphamide clearance are obtained using post hoc analysis.</description>
          <population>Eligible patients who received cyclophosphamide during a cycle of induction therapy and had samples collected for PK analysis..</population>
          <units>L/h/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.40" lower_limit="1.16" upper_limit="9.15"/>
                    <measurement group_id="O2" value="2.23" lower_limit="1.23" upper_limit="8.95"/>
                    <measurement group_id="O3" value="2.25" lower_limit="0.84" upper_limit="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cyclophosphamide Clearance in Consolidation Chemotherapy Cycle 1</title>
        <description>Cyclophosphamide plasma concentration-time data are collected in consolidation cycle 1. Individual estimates of cyclophosphamide clearance are obtained using post hoc analysis.</description>
        <time_frame>Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion</time_frame>
        <population>Eligible patients who received cyclophosphamide during consolidation cycle 1 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Cyclophosphamide Clearance in Consolidation Chemotherapy Cycle 1</title>
          <description>Cyclophosphamide plasma concentration-time data are collected in consolidation cycle 1. Individual estimates of cyclophosphamide clearance are obtained using post hoc analysis.</description>
          <population>Eligible patients who received cyclophosphamide during consolidation cycle 1 and had samples collected for PK analysis.</population>
          <units>L/h/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.39" lower_limit="1.65" upper_limit="3.44"/>
                    <measurement group_id="O2" value="2.08" lower_limit="1.97" upper_limit="2.62"/>
                    <measurement group_id="O3" value="2.43" lower_limit="1.29" upper_limit="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cyclophosphamide Clearance in Consolidation Chemotherapy Cycle 2</title>
        <description>Cyclophosphamide plasma concentration-time data are collected in consolidation cycle 2. Individual estimates of cyclophosphamide clearance are obtained using post hoc analysis.</description>
        <time_frame>Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion</time_frame>
        <population>Eligible patients who received cyclophosphamide during consolidation cycle 2 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Cyclophosphamide Clearance in Consolidation Chemotherapy Cycle 2</title>
          <description>Cyclophosphamide plasma concentration-time data are collected in consolidation cycle 2. Individual estimates of cyclophosphamide clearance are obtained using post hoc analysis.</description>
          <population>Eligible patients who received cyclophosphamide during consolidation cycle 2 and had samples collected for PK analysis.</population>
          <units>L/h/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.48" lower_limit="1.97" upper_limit="3.35"/>
                    <measurement group_id="O2" value="2.55" lower_limit="2.19" upper_limit="2.93"/>
                    <measurement group_id="O3" value="2.37" lower_limit="1.61" upper_limit="3.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cyclophosphamide Apparent Oral Clearance in Maintenance Chemotherapy Cycle A1</title>
        <description>Cyclophosphamide plasma concentration-time data are collected on day 1 of maintenance cycle A1. Individual estimates of cyclophosphamide apparent oral clearance are obtained using post hoc analysis.</description>
        <time_frame>Pre-dose, 0.5, 1.75, 3 and 6 hours post-dose</time_frame>
        <population>Eligible patients who received cyclophosphamide during maintenance cycle A1 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Cyclophosphamide Apparent Oral Clearance in Maintenance Chemotherapy Cycle A1</title>
          <description>Cyclophosphamide plasma concentration-time data are collected on day 1 of maintenance cycle A1. Individual estimates of cyclophosphamide apparent oral clearance are obtained using post hoc analysis.</description>
          <population>Eligible patients who received cyclophosphamide during maintenance cycle A1 and had samples collected for PK analysis.</population>
          <units>L/h/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.95" lower_limit="2.05" upper_limit="3.89"/>
                    <measurement group_id="O2" value="2.83" lower_limit="2.23" upper_limit="5.14"/>
                    <measurement group_id="O3" value="2.74" lower_limit="2.23" upper_limit="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cyclophosphamide AUC0-24h in Induction Chemotherapy</title>
        <description>Cyclophosphamide plasma concentration-time data are collected on day 9 in one cycle of induction chemotherapy. Individual estimates of cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis.</description>
        <time_frame>Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion</time_frame>
        <population>Eligible patients who received cyclophosphamide during a cycle of induction therapy and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Cyclophosphamide AUC0-24h in Induction Chemotherapy</title>
          <description>Cyclophosphamide plasma concentration-time data are collected on day 9 in one cycle of induction chemotherapy. Individual estimates of cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis.</description>
          <population>Eligible patients who received cyclophosphamide during a cycle of induction therapy and had samples collected for PK analysis.</population>
          <units>µmol·h/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2070" lower_limit="592" upper_limit="4158"/>
                    <measurement group_id="O2" value="2150" lower_limit="615" upper_limit="3430"/>
                    <measurement group_id="O3" value="2105" lower_limit="1523" upper_limit="5121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cyclophosphamide AUC0-24h in Consolidation Chemotherapy Cycle 1</title>
        <description>Cyclophosphamide plasma concentration-time data are collected in consolidation cycle 1. Individual estimates of cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis.</description>
        <time_frame>Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion</time_frame>
        <population>Eligible patients who received cyclophosphamide during consolidation cycle 1 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Cyclophosphamide AUC0-24h in Consolidation Chemotherapy Cycle 1</title>
          <description>Cyclophosphamide plasma concentration-time data are collected in consolidation cycle 1. Individual estimates of cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis.</description>
          <population>Eligible patients who received cyclophosphamide during consolidation cycle 1 and had samples collected for PK analysis.</population>
          <units>µmol·h/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1968" lower_limit="1480" upper_limit="2869"/>
                    <measurement group_id="O2" value="1504" lower_limit="617" upper_limit="2511"/>
                    <measurement group_id="O3" value="868" lower_limit="660" upper_limit="1498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cyclophosphamide AUC0-24h in Consolidation Chemotherapy Cycle 2</title>
        <description>Cyclophosphamide plasma concentration-time data are collected in consolidation cycle 2. Individual estimates of cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis.</description>
        <time_frame>Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion</time_frame>
        <population>Eligible patients who received cyclophosphamide during consolidation cycle 2 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Cyclophosphamide AUC0-24h in Consolidation Chemotherapy Cycle 2</title>
          <description>Cyclophosphamide plasma concentration-time data are collected in consolidation cycle 2. Individual estimates of cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis.</description>
          <population>Eligible patients who received cyclophosphamide during consolidation cycle 2 and had samples collected for PK analysis.</population>
          <units>µmol·h/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1966" lower_limit="1437" upper_limit="2519"/>
                    <measurement group_id="O2" value="799" lower_limit="740" upper_limit="2303"/>
                    <measurement group_id="O3" value="899" lower_limit="700" upper_limit="1240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cyclophosphamide AUC0-24h in Maintenance Chemotherapy Cycle A1</title>
        <description>Cyclophosphamide plasma concentration-time data are collected on day 1 of maintenance cycle A1. Individual estimates of cyclophosphamide AUC0-24h are obtained using post hoc analysis.</description>
        <time_frame>Pre-dose, 0.5, 1.75, 3, 6, and 24 hours post-dose</time_frame>
        <population>Eligible patients who received cyclophosphamide during maintenance cycle A1 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Cyclophosphamide AUC0-24h in Maintenance Chemotherapy Cycle A1</title>
          <description>Cyclophosphamide plasma concentration-time data are collected on day 1 of maintenance cycle A1. Individual estimates of cyclophosphamide AUC0-24h are obtained using post hoc analysis.</description>
          <population>Eligible patients who received cyclophosphamide during maintenance cycle A1 and had samples collected for PK analysis.</population>
          <units>µmol·h/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.9" lower_limit="25.3" upper_limit="51.3"/>
                    <measurement group_id="O2" value="38.7" lower_limit="21.2" upper_limit="54.9"/>
                    <measurement group_id="O3" value="42.2" lower_limit="28.0" upper_limit="53.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>4-OH Cyclophosphamide AUC0-24h in Induction Chemotherapy</title>
        <description>4-OH cyclophosphamide plasma concentration-time data are collected on day 9 in one cycle of induction chemotherapy. Individual estimates of 4-OH cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis.</description>
        <time_frame>Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion</time_frame>
        <population>Eligible patients who received cyclophosphamide during a cycle of induction therapy and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>4-OH Cyclophosphamide AUC0-24h in Induction Chemotherapy</title>
          <description>4-OH cyclophosphamide plasma concentration-time data are collected on day 9 in one cycle of induction chemotherapy. Individual estimates of 4-OH cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis.</description>
          <population>Eligible patients who received cyclophosphamide during a cycle of induction therapy and had samples collected for PK analysis.</population>
          <units>µmol·h/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.4" lower_limit="74.6" upper_limit="200.3"/>
                    <measurement group_id="O2" value="111.3" lower_limit="71.4" upper_limit="181.0"/>
                    <measurement group_id="O3" value="109.1" lower_limit="65.0" upper_limit="175.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>4-OH Cyclophosphamide AUC0-24h in Consolidation Chemotherapy Cycle 1</title>
        <description>4-OH cyclophosphamide plasma concentration-time data are collected in consolidation cycle 1. Individual estimates of 4-OH cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post- dose) are obtained using post hoc analysis.</description>
        <time_frame>Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion</time_frame>
        <population>Eligible patients who received cyclophosphamide during consolidation cycle 1 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>4-OH Cyclophosphamide AUC0-24h in Consolidation Chemotherapy Cycle 1</title>
          <description>4-OH cyclophosphamide plasma concentration-time data are collected in consolidation cycle 1. Individual estimates of 4-OH cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post- dose) are obtained using post hoc analysis.</description>
          <population>Eligible patients who received cyclophosphamide during consolidation cycle 1 and had samples collected for PK analysis.</population>
          <units>µmol·h/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.8" lower_limit="63.0" upper_limit="124.4"/>
                    <measurement group_id="O2" value="48.7" lower_limit="25.8" upper_limit="124.6"/>
                    <measurement group_id="O3" value="39.8" lower_limit="25.5" upper_limit="59.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>4-OH Cyclophosphamide AUC0-24h in Consolidation Chemotherapy Cycle 2</title>
        <description>4-OH cyclophosphamide plasma concentration-time data are collected in consolidation cycle 2. Individual estimates of 4-OH cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post- dose) are obtained using post hoc analysis.</description>
        <time_frame>Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion</time_frame>
        <population>Eligible patients who received cyclophosphamide during consolidation cycle 2 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>4-OH Cyclophosphamide AUC0-24h in Consolidation Chemotherapy Cycle 2</title>
          <description>4-OH cyclophosphamide plasma concentration-time data are collected in consolidation cycle 2. Individual estimates of 4-OH cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post- dose) are obtained using post hoc analysis.</description>
          <population>Eligible patients who received cyclophosphamide during consolidation cycle 2 and had samples collected for PK analysis.</population>
          <units>µmol·h/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.9" lower_limit="81.7" upper_limit="131.1"/>
                    <measurement group_id="O2" value="49.5" lower_limit="39.5" upper_limit="84.5"/>
                    <measurement group_id="O3" value="43.5" lower_limit="30.8" upper_limit="72.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>4-OH Cyclophosphamide AUC0-24h in Maintenance Chemotherapy Cycle A1</title>
        <description>4-OH cyclophosphamide plasma concentration-time data are collected on day 1 of maintenance cycle A1. Individual estimates of 4-OH cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis.</description>
        <time_frame>Pre-dose, 0.5, 1.75, 3, 6, and 24 hours post-dose</time_frame>
        <population>Eligible patients who received cyclophosphamide during maintenance cycle A1 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>4-OH Cyclophosphamide AUC0-24h in Maintenance Chemotherapy Cycle A1</title>
          <description>4-OH cyclophosphamide plasma concentration-time data are collected on day 1 of maintenance cycle A1. Individual estimates of 4-OH cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis.</description>
          <population>Eligible patients who received cyclophosphamide during maintenance cycle A1 and had samples collected for PK analysis.</population>
          <units>µmol·h/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" lower_limit="0.98" upper_limit="3.01"/>
                    <measurement group_id="O2" value="1.96" lower_limit="1.12" upper_limit="3.08"/>
                    <measurement group_id="O3" value="1.82" lower_limit="1.19" upper_limit="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CEPM AUC0-24h in Induction Chemotherapy</title>
        <description>Carboxyethylphosphoramide mustard (CEPM) plasma concentration-time data are collected on day 9 in one induction cycle. Individual estimates of CEPM AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis.</description>
        <time_frame>Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion</time_frame>
        <population>Eligible patients who received cyclophosphamide during a cycle of induction therapy and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>CEPM AUC0-24h in Induction Chemotherapy</title>
          <description>Carboxyethylphosphoramide mustard (CEPM) plasma concentration-time data are collected on day 9 in one induction cycle. Individual estimates of CEPM AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis.</description>
          <population>Eligible patients who received cyclophosphamide during a cycle of induction therapy and had samples collected for PK analysis.</population>
          <units>µmol·h/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.2" lower_limit="50.1" upper_limit="453.0"/>
                    <measurement group_id="O2" value="137.8" lower_limit="80.4" upper_limit="328.9"/>
                    <measurement group_id="O3" value="135.3" lower_limit="57.6" upper_limit="591.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CEPM AUC0-24h in Consolidation Chemotherapy Cycle 1</title>
        <description>Carboxyethylphosphoramide mustard (CEPM) plasma concentration-time data are collected in consolidation cycle 1. Individual estimates of CEPM AUC0-24h (area under concentration curve from time 0 to 24 hours post- dose) are obtained using post hoc analysis.</description>
        <time_frame>Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion</time_frame>
        <population>Eligible patients who received cyclophosphamide during consolidation cycle 1 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>CEPM AUC0-24h in Consolidation Chemotherapy Cycle 1</title>
          <description>Carboxyethylphosphoramide mustard (CEPM) plasma concentration-time data are collected in consolidation cycle 1. Individual estimates of CEPM AUC0-24h (area under concentration curve from time 0 to 24 hours post- dose) are obtained using post hoc analysis.</description>
          <population>Eligible patients who received cyclophosphamide during consolidation cycle 1 and had samples collected for PK analysis.</population>
          <units>µmol·h/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.9" lower_limit="90.8" upper_limit="272.9"/>
                    <measurement group_id="O2" value="62.2" lower_limit="48.8" upper_limit="193.9"/>
                    <measurement group_id="O3" value="51.8" lower_limit="18.9" upper_limit="97.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CEPM AUC0-24h in Consolidation Chemotherapy Cycle 2</title>
        <description>Carboxyethylphosphoramide mustard (CEPM) plasma concentration-time data are collected in consolidation cycle 2. Individual estimates of CEPM AUC0-24h (area under concentration curve from time 0 to 24 hours post- dose) are obtained using post hoc analysis.</description>
        <time_frame>Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion</time_frame>
        <population>Eligible patients who received cyclophosphamide during consolidation cycle 2 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>CEPM AUC0-24h in Consolidation Chemotherapy Cycle 2</title>
          <description>Carboxyethylphosphoramide mustard (CEPM) plasma concentration-time data are collected in consolidation cycle 2. Individual estimates of CEPM AUC0-24h (area under concentration curve from time 0 to 24 hours post- dose) are obtained using post hoc analysis.</description>
          <population>Eligible patients who received cyclophosphamide during consolidation cycle 2 and had samples collected for PK analysis.</population>
          <units>µmol·h/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.7" lower_limit="89.7" upper_limit="244.0"/>
                    <measurement group_id="O2" value="46.8" lower_limit="41.9" upper_limit="69.0"/>
                    <measurement group_id="O3" value="44.0" lower_limit="21.1" upper_limit="73.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CEPM AUC0-24h in Maintenance Chemotherapy Cycle A1</title>
        <description>Carboxyethylphosphoramide mustard (CEPM) plasma concentration-time data are collected on day 1 of maintenance cycle A1. Individual estimates of CEPM AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis.</description>
        <time_frame>Pre-dose, 0.5, 1.75, 3, 6, and 24 hours post-dose</time_frame>
        <population>Eligible patients who received cyclophosphamide during maintenance cycle A1 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>CEPM AUC0-24h in Maintenance Chemotherapy Cycle A1</title>
          <description>Carboxyethylphosphoramide mustard (CEPM) plasma concentration-time data are collected on day 1 of maintenance cycle A1. Individual estimates of CEPM AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis.</description>
          <population>Eligible patients who received cyclophosphamide during maintenance cycle A1 and had samples collected for PK analysis.</population>
          <units>µmol·h/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59" lower_limit="0.75" upper_limit="3.48"/>
                    <measurement group_id="O2" value="1.65" lower_limit="0.68" upper_limit="3.64"/>
                    <measurement group_id="O3" value="1.41" lower_limit="0.64" upper_limit="3.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Empirical Dosage Achieving Target System Exposure of Intravenous Topotecan</title>
        <description>Number of participants who successfully achieve target systemic exposure of intravenous topotecan after an empiric dosage during consolidation phase of therapy are reported.</description>
        <time_frame>Pre-infusion, 5 min., 1, and 3 hours from end of infusion</time_frame>
        <population>Eligible patients who received topotecan with empirical dosage during consolidation therapy were included in this analysis. Per protocol, low-risk and intermediate-risk patients did not receive topotecan during consolidation unless they experienced disease progression during induction. One such intermediate-risk patient was included.</population>
        <group_list>
          <group group_id="O1">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O2">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Empirical Dosage Achieving Target System Exposure of Intravenous Topotecan</title>
          <description>Number of participants who successfully achieve target systemic exposure of intravenous topotecan after an empiric dosage during consolidation phase of therapy are reported.</description>
          <population>Eligible patients who received topotecan with empirical dosage during consolidation therapy were included in this analysis. Per protocol, low-risk and intermediate-risk patients did not receive topotecan during consolidation unless they experienced disease progression during induction. One such intermediate-risk patient was included.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With PK-guided Dosage Adjustment Achieving Target System Exposure of Intravenous Topotecan</title>
        <description>Number of participants who successfully achieve target systemic exposure of intravenous topotecan after a pharmacokinetic-guided dosage adjustment during consolidation phase of therapy are reported.</description>
        <time_frame>Pre-infusion, 5 min., 1, and 3 hours from end of infusion</time_frame>
        <population>Eligible patients who received topotecan with PK-guided dosage adjustment during consolidation therapy were included in this analysis. Per protocol, low-risk and intermediate-risk patients did not receive topotecan during consolidation unless they experienced disease progression during induction. One such intermediate-risk patient was included.</population>
        <group_list>
          <group group_id="O1">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O2">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With PK-guided Dosage Adjustment Achieving Target System Exposure of Intravenous Topotecan</title>
          <description>Number of participants who successfully achieve target systemic exposure of intravenous topotecan after a pharmacokinetic-guided dosage adjustment during consolidation phase of therapy are reported.</description>
          <population>Eligible patients who received topotecan with PK-guided dosage adjustment during consolidation therapy were included in this analysis. Per protocol, low-risk and intermediate-risk patients did not receive topotecan during consolidation unless they experienced disease progression during induction. One such intermediate-risk patient was included.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Topotecan Clearance in Consolidation Chemotherapy</title>
        <description>Topotecan plasma concentration-time data are collected on day 1 of consolidation cycle 1 after a single IV dose. Individual estimates of topotecan clearance are obtained using post hoc analysis.</description>
        <time_frame>Pre-infusion, 5 min., 1, and 3 hours from end of infusion</time_frame>
        <population>Eligible patients who received intravenous topotecan during consolidation cycle 1 and had PK samples collected were included in this analysis. Per protocol, low- and intermediate-risk patients did not receive topotecan during consolidation unless they experienced disease progression during induction. One such intermediate-risk patient was included.</population>
        <group_list>
          <group group_id="O1">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O2">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Topotecan Clearance in Consolidation Chemotherapy</title>
          <description>Topotecan plasma concentration-time data are collected on day 1 of consolidation cycle 1 after a single IV dose. Individual estimates of topotecan clearance are obtained using post hoc analysis.</description>
          <population>Eligible patients who received intravenous topotecan during consolidation cycle 1 and had PK samples collected were included in this analysis. Per protocol, low- and intermediate-risk patients did not receive topotecan during consolidation unless they experienced disease progression during induction. One such intermediate-risk patient was included.</population>
          <units>L/h/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3" lower_limit="30.3" upper_limit="30.3"/>
                    <measurement group_id="O2" value="26.40" lower_limit="6.8" upper_limit="43.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Topotecan Apparent Oral Clearance in Maintenance Chemotherapy</title>
        <description>Topotecan plasma concentration-time data are collected on day 1 of maintenance cycle A1 after a single oral dose. Individual estimates of topotecan apparent oral clearance are obtained using post hoc analysis.</description>
        <time_frame>Pre-dose, 0.25, 1.5 and 6 hours post-dose</time_frame>
        <population>Eligible patients who received oral topotecan during maintenance therapy cycle A1 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Topotecan Apparent Oral Clearance in Maintenance Chemotherapy</title>
          <description>Topotecan plasma concentration-time data are collected on day 1 of maintenance cycle A1 after a single oral dose. Individual estimates of topotecan apparent oral clearance are obtained using post hoc analysis.</description>
          <population>Eligible patients who received oral topotecan during maintenance therapy cycle A1 and had samples collected for PK analysis.</population>
          <units>L/h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.4" lower_limit="12.3" upper_limit="54.6"/>
                    <measurement group_id="O2" value="41.0" lower_limit="24.4" upper_limit="62.7"/>
                    <measurement group_id="O3" value="44.6" lower_limit="18.1" upper_limit="57.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Topotecan AUC0-24h in Consolidation Chemotherapy</title>
        <description>Topotecan plasma concentration-time data are collected on day 1 of consolidation cycle 1 after a single IV dose. Individual estimates of topotecan AUC0-24h (area under concentration curve from time 0 to 24 hours post- dose) are obtained using post hoc analysis.</description>
        <time_frame>Pre-infusion, 5 min., 1, 3, and 24 hours from end of infusion</time_frame>
        <population>Eligible patients who received intravenous topotecan during consolidation cycle 1 and had PK samples collected were included in this analysis. Per protocol, low- and intermediate-risk patients did not receive topotecan during consolidation unless they experienced disease progression during induction. One such intermediate-risk patient was included.</population>
        <group_list>
          <group group_id="O1">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O2">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Topotecan AUC0-24h in Consolidation Chemotherapy</title>
          <description>Topotecan plasma concentration-time data are collected on day 1 of consolidation cycle 1 after a single IV dose. Individual estimates of topotecan AUC0-24h (area under concentration curve from time 0 to 24 hours post- dose) are obtained using post hoc analysis.</description>
          <population>Eligible patients who received intravenous topotecan during consolidation cycle 1 and had PK samples collected were included in this analysis. Per protocol, low- and intermediate-risk patients did not receive topotecan during consolidation unless they experienced disease progression during induction. One such intermediate-risk patient was included.</population>
          <units>µg·h/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117" lower_limit="117" upper_limit="117"/>
                    <measurement group_id="O2" value="116" lower_limit="90" upper_limit="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Topotecan AUC0-24h in Maintenance Chemotherapy</title>
        <description>Topotecan plasma concentration-time data are collected on day 1 of maintenance cycle A1 after a single oral dose. Individual estimates of topotecan AUC0-24h (area under concentration curve from time 0 to 24 hours post- dose) are obtained using post hoc analysis.</description>
        <time_frame>Pre-dose, 0.25, 1.5, 6, and 24 hours post-dose</time_frame>
        <population>Eligible patients who received oral topotecan during maintenance therapy cycle A1 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Topotecan AUC0-24h in Maintenance Chemotherapy</title>
          <description>Topotecan plasma concentration-time data are collected on day 1 of maintenance cycle A1 after a single oral dose. Individual estimates of topotecan AUC0-24h (area under concentration curve from time 0 to 24 hours post- dose) are obtained using post hoc analysis.</description>
          <population>Eligible patients who received oral topotecan during maintenance therapy cycle A1 and had samples collected for PK analysis.</population>
          <units>µg·h/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.90" lower_limit="9.04" upper_limit="24.36"/>
                    <measurement group_id="O2" value="11.60" lower_limit="7.93" upper_limit="20.50"/>
                    <measurement group_id="O3" value="10.33" lower_limit="7.96" upper_limit="16.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erlotinib Apparent Oral Clearance</title>
        <description>Erlotinib plasma concentration-time data are collected on day 1 of maintenance cycle B2. Individual estimates of erlotinib apparent oral clearance are obtained using post hoc analysis.</description>
        <time_frame>Pre-dose, 1, 2, 4, 8, and 24 hours post-dose</time_frame>
        <population>Eligible patients who received oral erlotinib during maintenance therapy cycle B2 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Erlotinib Apparent Oral Clearance</title>
          <description>Erlotinib plasma concentration-time data are collected on day 1 of maintenance cycle B2. Individual estimates of erlotinib apparent oral clearance are obtained using post hoc analysis.</description>
          <population>Eligible patients who received oral erlotinib during maintenance therapy cycle B2 and had samples collected for PK analysis.</population>
          <units>L/h/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.53" lower_limit="3.13" upper_limit="18.55"/>
                    <measurement group_id="O2" value="7.79" lower_limit="3.87" upper_limit="16.84"/>
                    <measurement group_id="O3" value="8.40" lower_limit="5.96" upper_limit="10.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erlotinib Apparent Volume of Central Compartment</title>
        <description>Erlotinib plasma concentration-time data are collected on day 1 of maintenance cycle B2. Individual estimates of erlotinib apparent volume of central compartment are obtained using post hoc analysis.</description>
        <time_frame>Pre-dose, 1, 2, 4, 8, and 24 hours post-dose</time_frame>
        <population>Eligible patients who received oral erlotinib during maintenance therapy cycle B2 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Erlotinib Apparent Volume of Central Compartment</title>
          <description>Erlotinib plasma concentration-time data are collected on day 1 of maintenance cycle B2. Individual estimates of erlotinib apparent volume of central compartment are obtained using post hoc analysis.</description>
          <population>Eligible patients who received oral erlotinib during maintenance therapy cycle B2 and had samples collected for PK analysis.</population>
          <units>L/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.9" lower_limit="39.5" upper_limit="233.7"/>
                    <measurement group_id="O2" value="61.7" lower_limit="41.3" upper_limit="119.0"/>
                    <measurement group_id="O3" value="104.8" lower_limit="47.6" upper_limit="109.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erlotinib AUC0-24h</title>
        <description>Erlotinib plasma concentration-time data are collected on day 1 of maintenance cycle B2. Individual estimates of erlotinib AUC0-24h (area under concentration curve from 0 to 24 hours post-dose) are obtained using post hoc analysis.</description>
        <time_frame>Pre-dose, 1, 2, 4, 8, and 24 hours post-dose</time_frame>
        <population>Eligible patients who received oral erlotinib during maintenance therapy cycle B2 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>Erlotinib AUC0-24h</title>
          <description>Erlotinib plasma concentration-time data are collected on day 1 of maintenance cycle B2. Individual estimates of erlotinib AUC0-24h (area under concentration curve from 0 to 24 hours post-dose) are obtained using post hoc analysis.</description>
          <population>Eligible patients who received oral erlotinib during maintenance therapy cycle B2 and had samples collected for PK analysis.</population>
          <units>µmol·h/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0" lower_limit="7.2" upper_limit="64.8"/>
                    <measurement group_id="O2" value="23.5" lower_limit="12.5" upper_limit="48.6"/>
                    <measurement group_id="O3" value="22.0" lower_limit="13.8" upper_limit="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OSI-420 AUC0-24h</title>
        <description>Erlotinib metabolite OSI-420 plasma concentration-time data are collected on day 1 of maintenance cycle B2. Individual estimates of OSI-420 AUC0-24h (area under concentration curve from 0 to 24 hours post-dose) are obtained using post hoc analysis.</description>
        <time_frame>Pre-dose, 1, 2, 4, 8, and 24 hours post-dose</time_frame>
        <population>Eligible patients who received oral erlotinib during maintenance therapy cycle B2 and had samples collected for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-Risk Group</title>
            <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma</description>
          </group>
          <group group_id="O2">
            <title>Intermediate-Risk Group</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Patients with central nervous system (CNS) metastatic disease</description>
          </group>
        </group_list>
        <measure>
          <title>OSI-420 AUC0-24h</title>
          <description>Erlotinib metabolite OSI-420 plasma concentration-time data are collected on day 1 of maintenance cycle B2. Individual estimates of OSI-420 AUC0-24h (area under concentration curve from 0 to 24 hours post-dose) are obtained using post hoc analysis.</description>
          <population>Eligible patients who received oral erlotinib during maintenance therapy cycle B2 and had samples collected for PK analysis.</population>
          <units>µmol·h/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" lower_limit="0.73" upper_limit="5.98"/>
                    <measurement group_id="O2" value="1.81" lower_limit="1.17" upper_limit="6.97"/>
                    <measurement group_id="O3" value="1.62" lower_limit="1.25" upper_limit="2.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Local Disease Progression</title>
        <description>Local failure was defined as the interval from end of RT to date of local failure (or combined local + distant failure). Competing events were distant failure or second malignancy. Patients without an event were censored at date of last contact. The 1-year cumulative incidence was estimated and reported with a 95% confidence interval.</description>
        <time_frame>1 year after completion of radiation therapy for last patient</time_frame>
        <population>Eligible intermediate-risk patients who received focal radiation were included in this analysis. Of the 156 intermediate risk patients, 121 started radiation.</population>
        <group_list>
          <group group_id="O1">
            <title>Intermediate-risk Patients Who Received Focal Radiation</title>
            <description>Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a surgical gross total resection (GTR), other histologic diagnoses with no metastatic disease who received induction chemotherapy and intermediate-risk therapy that included focal radiation.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Local Disease Progression</title>
          <description>Local failure was defined as the interval from end of RT to date of local failure (or combined local + distant failure). Competing events were distant failure or second malignancy. Patients without an event were censored at date of last contact. The 1-year cumulative incidence was estimated and reported with a 95% confidence interval.</description>
          <population>Eligible intermediate-risk patients who received focal radiation were included in this analysis. Of the 156 intermediate risk patients, 121 started radiation.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" lower_limit="7.2" upper_limit="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Distant Disease Progression</title>
        <description>Distant failure was defined as the interval from end of RT to date of distant failure (or combined local + distant failure). Competing events were local failure or second malignancy. Patients without an event were censored at date of last contact. The 1-year cumulative incidence was estimated and reported with a 95% confidence interval.</description>
        <time_frame>1 year after completion of radiation therapy for last patient</time_frame>
        <population>Eligible intermediate-risk patients who received focal radiation were included in this analysis. Of the 156 intermediate risk patients, 121 started radiation.</population>
        <group_list>
          <group group_id="O1">
            <title>Intermediate-risk Patients Who Received Focal Radiation</title>
            <description>Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease who received induction chemotherapy and intermediate-risk therapy that included focal radiation.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Distant Disease Progression</title>
          <description>Distant failure was defined as the interval from end of RT to date of distant failure (or combined local + distant failure). Competing events were local failure or second malignancy. Patients without an event were censored at date of last contact. The 1-year cumulative incidence was estimated and reported with a 95% confidence interval.</description>
          <population>Eligible intermediate-risk patients who received focal radiation were included in this analysis. Of the 156 intermediate risk patients, 121 started radiation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" lower_limit="17.8" upper_limit="33.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events grades 3, 4, and 5 which occur during treatment and for 30 days after the end of treatment, and events which occur later than 30 days after the end of treatment which are felt to be at least possibly related to treatment, to the time of off study, were collected with some exceptions noted in the additional description section.</time_frame>
      <desc>Per protocol, some grade 3 and 4 hematologic toxicities, grade 3 elevation in serum ALT or AST, grade 3 and 4 electrolyte abnormalities, and total parenteral nutrition or intravenous fluids administered to prevent significant weight loss/malnutrition were not collected, especially if they occurred from the beginning of induction chemotherapy. The one patient in the high-risk group who did not start therapy due to early disease progression was excluded from adverse event results.</desc>
      <group_list>
        <group group_id="E1">
          <title>Low-Risk Group</title>
          <description>Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.</description>
        </group>
        <group group_id="E2">
          <title>Intermediate-Risk Group</title>
          <description>Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.</description>
        </group>
        <group group_id="E3">
          <title>High-Risk Group</title>
          <description>Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing: patients with/without baseline audiogram and enrolled in a monitoring program</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam), Oral cavity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Perforation, GI, Duodenum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L), Pharynx</sub_title>
                <description>Documented clinically or microbiologically</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Infection, Upper airway NOS</sub_title>
                <description>Documented clinically or microbiologically with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, Blood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, Catheter-related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, Eye NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis (metabolic or respiratory)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Irritability (children &lt;3 years of age)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Neurology - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Neuropathy: motor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Somnolence/depressed level of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Speech impairment (e.g., dysphasia or aphasia)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage/Bleeding - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="145" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Fever of unknown origin without clinically or microbiologically documented infection (ANC &lt;1.0 x 10e9/L, fever &gt;=38.5 degrees C)</description>
                <counts group_id="E1" events="83" subjects_affected="36" subjects_at_risk="57"/>
                <counts group_id="E2" events="169" subjects_affected="92" subjects_at_risk="156"/>
                <counts group_id="E3" events="120" subjects_affected="48" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="60" subjects_affected="32" subjects_at_risk="57"/>
                <counts group_id="E2" events="124" subjects_affected="57" subjects_at_risk="156"/>
                <counts group_id="E3" events="20" subjects_affected="10" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="38" subjects_affected="24" subjects_at_risk="57"/>
                <counts group_id="E2" events="83" subjects_affected="45" subjects_at_risk="156"/>
                <counts group_id="E3" events="11" subjects_affected="6" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="57"/>
                <counts group_id="E2" events="20" subjects_affected="9" subjects_at_risk="156"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="19" subjects_affected="7" subjects_at_risk="57"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing: patients with/without baseline audiogram and enrolled in a monitoring program</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="57"/>
                <counts group_id="E2" events="32" subjects_affected="25" subjects_at_risk="156"/>
                <counts group_id="E3" events="29" subjects_affected="22" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="156"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="156"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (functional/symptomatic), Oral cavity</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="156"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam), Oral cavity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, Catheter-related</sub_title>
                <description>Documented clinically or microbiologically with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L)</description>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="57"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="156"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, Catheter-related</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="57"/>
                <counts group_id="E2" events="26" subjects_affected="19" subjects_at_risk="156"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Colitis, infectious (e.g., Clostridium difficile)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Infection, Skin (cellulitis)</sub_title>
                <description>Documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="156"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Infection, Blood</sub_title>
                <description>Documented clinically or microbiologically with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L)</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, Blood</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="156"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Infection, Upper airway NOS</sub_title>
                <description>Documented clinically or microbiologically with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Infection, Urinary tract NOS</sub_title>
                <description>Documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E3" events="13" subjects_affected="9" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Results for the some of the secondary objectives are not available yet. These results will be posted as they become available.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Amar Gajjar, MD</name_or_title>
      <organization>St. Jude Children's Research Hospital</organization>
      <phone>866-278-5833</phone>
      <email>amar.gajjar@stjude.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

